Crispr-cas13 system and use thereof

MYPI2025001302A0Undetermined Publication Date: 2024-02-26GUANGZHOU REFORGENE MEDICINE CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025001302
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-24
Filing Date
2023-08-25
Publication Date
2024-02-26

AI Technical Summary

Technical Problem

The existing CRISPR-Cas13 system has low editing efficiency and high cytotoxicity in mammalian cells, making it difficult to meet the needs of compact size and low cytotoxicity.

Method used

A CRISPR-Cas13 system targeting RNA was developed. The amino acid sequence of the Cas13 protein has at least 90% sequence identity compared with SEQ ID NO:1, and the RNA cleavage activity is reduced by introducing specific mutations to form and guide polynucleosides. Acidic CRISPR complex achieves specific binding of target RNA.

Benefits of technology

It improves RNA editing efficiency in mammalian cells, reduces cytotoxicity, meets the needs of compact size and low cytotoxicity, and provides an efficient RNA targeting tool.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025001302_DRAWING_001
    Figure PI2025001302_DRAWING_001
  • Figure PI2025001302_DRAWING_002
    Figure PI2025001302_DRAWING_002
  • Figure PI2025001302_DRAWING_003
    Figure PI2025001302_DRAWING_003
Patent Text Reader

Abstract

The present invention relates to a CRISPR-Cas13 system and use thereof, and also relates to a Cas13 protein, a fusion protein, and a guide polynucleotide. The Cas13 protein has at least 90% sequence identity compared to SEQ ID NO: 1. The fusion protein comprises the Cas13 protein fused to a protein domain and / or a polypeptide tag. The guide polynucleotide comprises a same-direction repetition sequence and a guide sequence that has been engineered to hybridize with the target RNA. The same-direction repetition sequence has at least 70% sequence identity to any of SEQ ID NOs: 3 and 80-87. The CRISPR-Cas13 system comprises the Cas13 protein that has at least 90% sequence identity to SEQ ID NO: 1, or a coding nucleic acid therefor, and the guide polynucleotide or a coding nucleic acid therefor.
Need to check novelty before this filing date? Find Prior Art

Description

A CRISPR-Cas13 system and its application Technical Field

[0001] The present disclosure relates to the field of CRISPR gene editing, and specifically to a CRISPR-Cas13 system and its applications. Background Art

[0002] CRISPR-Cas13 is an RNA targeting and editing system based on the bacterial immune system that protects bacteria from viruses. The CRISPR-Cas13 system is similar to the CRISPR-Cas9 system, but unlike the Cas9 protein, which targets DNA, the Cas13 protein targets RNA.

[0003] CRISPR-Cas13 belongs to the Type VI CRISPR-Cas13 system, which contains a single effector protein Cas13. Currently, CRISPR-Cas13 can be divided into multiple subtypes (such as Cas13a, Cas13b, Cas13c and Cas13d) based on phylogeny. However, there is still an urgent need to discover new Cas13 systems with compact size (for example, suitable for AAV delivery), high editing efficiency in mammalian cells (for example, RNA targeting / cleavage activity) and / or low cytotoxicity (for example, cell dormancy and apoptosis caused by bystander RNA degradation).

[0004] Summary of the Invention

[0005] To address the technical problem in the prior art of the lack of a Cas13 system with compact size, high editing efficiency in mammalian cells and / or low cytotoxicity, the present disclosure provides a CRISPR-Cas13 system targeting target RNA and its application.

[0006] One aspect of the present disclosure relates to a Cas13 protein having an amino acid sequence having at least 90% sequence identity compared to SEQ ID NO: 1.

[0007] In some embodiments, the Cas13 protein is capable of forming a CRISPR complex with a guide polynucleotide comprising a direct repeat sequence linked to a guide sequence that is engineered to hybridize to a target RNA.

[0008] In some embodiments, the Cas13 protein is capable of forming a CRISPR complex with a guide polynucleotide, and the CRISPR complex is capable of specifically binding to a target RNA sequence.

[0009] In some embodiments, the Cas13 protein is capable of forming a CRISPR complex with a guide polynucleotide comprising a direct repeat sequence linked to a guide sequence engineered to direct sequence-specific binding of the CRISPR complex to a target RNA.

[0010] In some embodiments, the amino acid sequence of the Cas13 protein has at least 95% sequence identity compared to SEQ ID NO: 1. In some embodiments, the amino acid sequence of the Cas13 protein has at least 96% sequence identity compared to SEQ ID NO: 1. In some embodiments, the amino acid sequence of the Cas13 protein has at least 97% sequence identity compared to SEQ ID NO: 1. In some embodiments, the amino acid sequence of the Cas13 protein has at least 98% sequence identity compared to SEQ ID NO: 1. In some embodiments, the amino acid sequence of the Cas13 protein has at least 99% sequence identity compared to SEQ ID NO: 1. In some embodiments, the amino acid sequence of the Cas13 protein has at least 99.5% sequence identity compared to SEQ ID NO: 1. In some embodiments, the amino acid sequence of the Cas13 protein is as shown in SEQ ID NO: 1.

[0011] The sequence of the present disclosure is SEQ ID NO: 1 Cas13 protein (i.e., C13-2 protein) is based on the bioinformatics analysis of prokaryotic genomes and metagenomes in the CNGB database (China National Gene Bank) and subsequent activity verification and identification. In some embodiments, the Cas13 protein disclosed herein is from a species (species) comprising a genome having an average nucleotide identity (ANI) ≥ 95% with the genome numbered CNA0009596 in the CNGB database.

[0012] Average nucleotide identity (ANI) is an indicator that evaluates the similarity of all orthologous protein-coding genes between two genomes at the nucleic acid level. For bacteria / archaea, the threshold value ANI = 95% is generally used as the basis for judging whether they are the same species (Richter M, Rosselló-Móra R. Shifting the genomic gold standard for the prokaryotic species definition. Proc Natl Acad Sci US A. 2009 Nov 10; 106(45): 19126-31). Therefore, this disclosure is defined by the above threshold value, and species with an ANI value of ≥ 95% of the reference genome are considered to be the same species. The Cas13 protein therein has homology with the protein claimed in this disclosure and has similar functions, which falls within the scope of this disclosure. ANI analysis tools include programs such as FastANI and JSpecies.

[0013] In some embodiments, the amino acid sequence of the Cas13 protein comprises one, two, three, four, five, six, seven or more mutations compared to SEQ ID NO: 1, such as a single amino acid insertion, a single amino acid deletion, a single amino acid substitution, or a combination thereof.

[0014] In some embodiments, the Cas13 protein comprises one or more mutations in the catalytic domain and has reduced RNA cleavage activity. In some embodiments, the Cas13 protein comprises a mutation in the catalytic domain and has reduced RNA cleavage activity. In some embodiments, the Cas13 protein comprises one or more mutations in one or both HEPN domains and substantially lacks RNA cleavage activity. In some embodiments, the Cas13 protein comprises a mutation in any one HEPN domain and substantially lacks RNA cleavage activity.

[0015] The “substantially lacking RNA cleavage activity” refers to retaining only ≤50%, ≤40%, ≤30%, ≤20%, ≤10%, ≤5% or ≤1% RNA cleavage activity compared to the wild-type Cas13 protein, or no detectable RNA cleavage activity.

[0016] In some embodiments, the RxxxxH motif (x represents any amino acid, RxxxxH can also be written as Rx4H or R4xH) of the Cas13 protein comprises one or more mutations and substantially lacks RNA cleavage activity.

[0017] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to the RxxxxH motif at positions 210-215, the RxxxxH motif at positions 750-755, and / or the RxxxxH motif at positions 785-790 of a reference protein as shown in SEQ ID NO: 1.

[0018] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to the RxxxxH motif at positions 210-215 of the reference protein as shown in SEQ ID NO: 1. In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to the RxxxxH motif at positions 750-755 of the reference protein as shown in SEQ ID NO: 1. In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to the RxxxxH motif at positions 785-790 of the reference protein as shown in SEQ ID NO: 1.

[0019] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to the RxxxxH motif at positions 210-215 and the RxxxxH motif at positions 750-755 of the reference protein as shown in SEQ ID NO: 1.

[0020] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to the RxxxxH motif at positions 210-215 and the RxxxxH motif at positions 785-790 of the reference protein as shown in SEQ ID NO: 1.

[0021] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to the RxxxxH motif at positions 750-755 and the RxxxxH motif at positions 785-790 of the reference protein as shown in SEQ ID NO: 1.

[0022] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to the RxxxxH motif at positions 210-215, the RxxxxH motif at positions 750-755, and the RxxxxH motif at positions 785-790 of the reference protein as shown in SEQ ID NO: 1.

[0023] In some embodiments, the RxxxxH motif is mutated to AxxxxH, RxxxxA, or AxxxxA. In some embodiments, the RxxxxH motif is mutated to AxxxxH. In some embodiments, the RxxxxH motif is mutated to RxxxxA. In some embodiments, the RxxxxH motif is mutated to AxxxxA.

[0024] In some embodiments, the Cas13 protein comprises 1, 2, 3, 4, 5, or 6 mutations at positions corresponding to amino acid residues R210, H215, R750, H755, R785, and / or H790 of a reference protein as shown in SEQ ID NO: 1. In some embodiments, the Cas13 protein is mutated to A (alanine) at positions corresponding to amino acid residues R210, H215, R750, H755, R785, and / or H790 of a reference protein as shown in SEQ ID NO: 1.

[0025] In some embodiments, the amino acid sequence of the Cas13 protein comprises mutations at positions corresponding to amino acid residues R210 and H215 of the reference protein as shown in SEQ ID NO: 1. In some embodiments, the amino acid sequence of the Cas13 protein comprises mutations at positions corresponding to amino acid residues R750 and H755 of the reference protein as shown in SEQ ID NO: 1. In some embodiments, the amino acid sequence of the Cas13 protein comprises mutations at positions corresponding to amino acid residues R785 and H790 of the reference protein as shown in SEQ ID NO: 1.

[0026] In some embodiments, the amino acid sequence of the Cas13 protein comprises mutations at positions corresponding to amino acid residues R210, H215, R750, and H755 of the reference protein as shown in SEQ ID NO: 1.

[0027] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R750, H755, R785, and H790 of the reference protein set forth in SEQ ID NO: 1.

[0028] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R210, H215, R785 and / or H790 of the reference protein set forth in SEQ ID NO: 1.

[0029] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R210, H215, R750, H755, R785, and H790 of the reference protein set forth in SEQ ID NO: 1.

[0030] In some embodiments, the corresponding positions of R210, R750, or R785 are mutated to A. In some embodiments, the corresponding positions of H215, H755, or H790 are mutated to A. In some embodiments, the corresponding positions of R210, H215, R750, H755, R785, and H790 are all mutated to A.

[0031] In some embodiments, the Cas13 protein is obtained by introducing mutations into the RxxxxH motif at positions 210-215, the RxxxxH motif at positions 750-755, and / or the RxxxxH motif at positions 785-790 of the sequence shown in SEQ ID NO: 1.

[0032] In some embodiments, the Cas13 protein is obtained by introducing 1, 2, 3, 4, 5 or 6 mutations at positions R210, H215, R750, H755, R785 and / or H790 of the sequence shown in SEQ ID NO: 1. In some embodiments, the Cas13 protein is obtained by mutating positions R210, H215, R750, H755, R785 and / or H790 of the sequence shown in SEQ ID NO: 1 to A (alanine).

[0033] In some embodiments, the Cas13 protein is obtained by mutating R210, H215, R785, and H790 of the sequence as shown in SEQ ID NO: 1 to A. In some embodiments, the Cas13 protein is obtained by mutating R210, H215, R750, and H755 of the sequence as shown in SEQ ID NO: 1 to A. In some embodiments, the Cas13 protein is obtained by mutating R750, H755, R785, and H790 of the sequence as shown in SEQ ID NO: 1 to A. In some embodiments, the Cas13 protein is obtained by mutating R210, H215, R750, H755, R785, and H790 of the sequence as shown in SEQ ID NO: 1 to A.

[0034] In some embodiments, the Cas13 protein comprises at least one mutation at a position corresponding to amino acid residues 40-91, 146-153, 158-176, 182-209, 216-253, 271-287, 341-353, 379-424, 456-477, 521-557, 575-588, 609-625, 700-721, 724-783, 796-815, 828-852, or 880-893 of a reference protein as set forth in SEQ ID NO: 1.

[0035] In some embodiments, the Cas13 protein comprises any one or more mutations at positions corresponding to the following amino acid residues of the reference protein as shown in SEQ ID NO: 1: R11, N34, R35, R47, R58, R63, R64, N68, N87, N265, N274, R276, R290, R294, N299, N303, R308, R314, R320, R328, N332, R341, N346, R358, N372, N383, N390, N394, R47+R290, R47+R314, R290+R314, R47+R290+R314, R308+N6 8. N394+N68, N87+N68, R308+N265, N394+N265, N87+N265, R308+N68+N265, N87+N68+N265, T7, A16, S260, A263, M266, N274, F288, M 302, N303, L304, V305, I311, D313, H324, P326, H327, N332, N346, T353, T360, E365, A373, M380, S382, K395, Y396, D402, D411, S418.

[0036] In some embodiments, the Cas13 protein comprises any one or more mutations at positions corresponding to the following amino acid residues of the reference protein as shown in SEQ ID NO: 1, compared to the reference protein as shown in SEQ ID NO: 1: R11, N34, R35, R47, R58, R63, R64, N68, N87, N265, N274, R276, R290, R294, N299, N303, R308, and R314.

[0037] In some embodiments, the Cas13 protein comprises any one or more mutations at positions corresponding to the following amino acid residues of the reference protein as shown in SEQ ID NO: 1, as compared to the reference protein as shown in SEQ ID NO: 1: R47+R290, R47+R314, R290+R314, R47+R290+R314, N394+N265, N87+N265, A263, M266, N274, F288, V305, I311, D313, H324, T360, E365, A373, M380, D402, D411, S418.

[0038] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue R11 of the reference protein set forth in SEQ ID NO: 1.

[0039] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue N34 of the reference protein set forth in SEQ ID NO: 1.

[0040] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue R35 of the reference protein set forth in SEQ ID NO: 1.

[0041] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue R47 of the reference protein set forth in SEQ ID NO: 1.

[0042] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue R58 of the reference protein set forth in SEQ ID NO: 1.

[0043] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue R63 of the reference protein set forth in SEQ ID NO: 1.

[0044] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue R64 of the reference protein set forth in SEQ ID NO: 1.

[0045] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue N68 of the reference protein set forth in SEQ ID NO: 1.

[0046] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue N87 of the reference protein set forth in SEQ ID NO: 1.

[0047] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue N265 of the reference protein set forth in SEQ ID NO: 1.

[0048] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue N274 of the reference protein set forth in SEQ ID NO: 1.

[0049] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue R276 of the reference protein set forth in SEQ ID NO: 1.

[0050] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue R290 of the reference protein set forth in SEQ ID NO: 1.

[0051] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue R294 of the reference protein set forth in SEQ ID NO: 1.

[0052] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue N299 of the reference protein set forth in SEQ ID NO: 1.

[0053] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue N303 of the reference protein set forth in SEQ ID NO: 1.

[0054] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue R308 of the reference protein set forth in SEQ ID NO: 1.

[0055] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue R314 of the reference protein set forth in SEQ ID NO: 1.

[0056] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue R320 of the reference protein set forth in SEQ ID NO: 1.

[0057] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue R328 of the reference protein set forth in SEQ ID NO: 1.

[0058] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue N332 of the reference protein set forth in SEQ ID NO: 1.

[0059] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue R341 of the reference protein set forth in SEQ ID NO: 1.

[0060] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue N346 of the reference protein set forth in SEQ ID NO: 1.

[0061] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue R358 of the reference protein set forth in SEQ ID NO: 1.

[0062] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue N372 of the reference protein set forth in SEQ ID NO: 1.

[0063] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue N383 of the reference protein set forth in SEQ ID NO: 1.

[0064] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue N390 of the reference protein set forth in SEQ ID NO: 1.

[0065] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue N394 of the reference protein set forth in SEQ ID NO: 1.

[0066] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R47 and R290 of the reference protein set forth in SEQ ID NO: 1.

[0067] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R47 and R314 of the reference protein set forth in SEQ ID NO: 1.

[0068] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R290 and R314 of the reference protein set forth in SEQ ID NO: 1.

[0069] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R47, R290, and R314 of the reference protein set forth in SEQ ID NO: 1.

[0070] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R308 and N68 of the reference protein set forth in SEQ ID NO: 1.

[0071] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues N394 and N68 of the reference protein set forth in SEQ ID NO: 1.

[0072] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues N87 and N68 of the reference protein set forth in SEQ ID NO: 1.

[0073] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R308 and N265 of the reference protein set forth in SEQ ID NO: 1.

[0074] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues N394 and N265 of the reference protein set forth in SEQ ID NO: 1.

[0075] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues N87 and N265 of the reference protein set forth in SEQ ID NO: 1.

[0076] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R308, N68, and N265 of the reference protein set forth in SEQ ID NO: 1.

[0077] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues N87, N68, and N265 of the reference protein set forth in SEQ ID NO: 1.

[0078] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue T7 of the reference protein set forth in SEQ ID NO: 1.

[0079] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue A16 of the reference protein set forth in SEQ ID NO: 1.

[0080] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue S260 of the reference protein set forth in SEQ ID NO: 1.

[0081] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue A263 of the reference protein set forth in SEQ ID NO: 1.

[0082] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue M266 of the reference protein set forth in SEQ ID NO: 1.

[0083] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue N274 of the reference protein set forth in SEQ ID NO: 1.

[0084] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue F288 of the reference protein set forth in SEQ ID NO: 1.

[0085] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue M302 of the reference protein set forth in SEQ ID NO: 1.

[0086] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue N303 of the reference protein set forth in SEQ ID NO: 1.

[0087] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue L304 of the reference protein set forth in SEQ ID NO: 1.

[0088] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue V305 of the reference protein set forth in SEQ ID NO: 1.

[0089] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue 1311 of the reference protein set forth in SEQ ID NO: 1.

[0090] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue D313 of the reference protein set forth in SEQ ID NO: 1.

[0091] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue H324 of the reference protein set forth in SEQ ID NO: 1.

[0092] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue P326 of the reference protein set forth in SEQ ID NO: 1.

[0093] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue H327 of the reference protein set forth in SEQ ID NO: 1.

[0094] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue N332 of the reference protein set forth in SEQ ID NO: 1.

[0095] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue N346 of the reference protein set forth in SEQ ID NO: 1.

[0096] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue T353 of the reference protein set forth in SEQ ID NO: 1.

[0097] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue T360 of the reference protein set forth in SEQ ID NO: 1.

[0098] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue E365 of the reference protein set forth in SEQ ID NO: 1.

[0099] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue A373 of the reference protein set forth in SEQ ID NO: 1.

[0100] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue M380 of the reference protein set forth in SEQ ID NO: 1.

[0101] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue S382 of the reference protein set forth in SEQ ID NO: 1.

[0102] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue K395 of the reference protein set forth in SEQ ID NO: 1.

[0103] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue Y396 of the reference protein set forth in SEQ ID NO: 1.

[0104] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue D402 of the reference protein set forth in SEQ ID NO: 1.

[0105] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue D411 of the reference protein set forth in SEQ ID NO: 1.

[0106] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to amino acid residue S418 of the reference protein set forth in SEQ ID NO: 1.

[0107] In some embodiments, compared to the reference protein shown in SEQ ID NO: 1, the Cas13 protein is mutated to the same amino acid residue at the corresponding position of the mutation site of the reference protein shown in SEQ ID NO: 1 in Table 24 or Table 29.

[0108] In some embodiments, compared to the reference protein as shown in SEQ ID NO: 1, the Cas13 protein comprises the same mutation at the corresponding position of the mutation site of the reference protein shown in SEQ ID NO: 1 in Table 24 or Table 29.

[0109] In some embodiments, the Cas13 protein is obtained by introducing any one or more mutations at the following positions of the sequence as shown in SEQ ID NO: 1: R11, N34, R35, R47, R58, R63, R64, N68, N87, N265, N274, R276, R290, R294, N299, N303, R308, R314, R320, R328, N332, R341, N346, R358, N372, N383, N390, N394, R47+R290, R47+R314, R290+R314, R47+R290+R314, R308+N68, N , N346, T353, T360, E365, A373, M380, S382, K395, Y396, D402, D411, and S418.

[0110] In some embodiments, the Cas13 protein is obtained by introducing any one or more mutations at the following positions of the sequence as shown in SEQ ID NO: 1: N34, R64, N68, N265, R276, R294, N299, R314, R47+R290, R47+R314, R290+R314, R47+R290+R314, N394+N265, N87+N265, A263, M266, N274, F288, V305, I311, D313, H324, T360, E365, A373, M380, D402 and D411.

[0111] In some embodiments, the Cas13 protein is obtained by introducing any one or more mutations in Table 24 or Table 29 into the sequence shown in SEQ ID NO: 1.

[0112] In some embodiments, the Cas13 protein is obtained by deleting the sequence at the corresponding positions of amino acid residues 91-120, 141-180, 211-240, 331-360, 351-400, 431-460, 461-500, 511-550, 611-640, 631-660, 661-690, 691-760, 821-860, or 861-890 of the reference protein as shown in SEQ ID NO: 1.

[0113] In some embodiments, the Cas13 protein comprises a deletion of one or more amino acids at positions corresponding to amino acid residues 348-350, 521-556, or 883-893 of a reference protein as shown in SEQ ID NO: 1.

[0114] In some embodiments, the sequence deletion is deleted from ≤300, ≤200, ≤150, ≤100, ≤90, ≤80, ≤70, ≤60, ≤50, ≤40, ≤30, ≤20, or ≤10 amino acid residues.

[0115] In some embodiments, the Cas13 protein is obtained by deleting the sequence of SEQ ID NO: 1 at positions 91-120, 141-180, 211-240, 331-360, 351-400, 431-460, 461-500, 511-550, 611-640, 631-660, 661-690, 691-760, 821-860, or 861-890.

[0116] The sequence deletion is a deletion of one or more amino acid residues.

[0117] Another aspect of the disclosure relates to fusion proteins.

[0118] In some embodiments of the present disclosure, the fusion protein comprises the Cas13 protein or a functional fragment thereof described herein, and any one or more of the following fused to the Cas13 protein or a functional fragment thereof: a cytosine deaminase domain, an adenosine deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter domain, an affinity domain, a subcellular localization signal, a reporter tag, and an affinity tag.

[0119] In some embodiments of the present disclosure, the fusion protein comprises the Cas13 protein or a functional fragment thereof described herein, and any one or more of the following fused to the Cas13 protein or a functional fragment thereof: a cytosine deaminase domain, an adenosine deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a subcellular localization signal, a reporter tag, and an affinity tag.

[0120] In some embodiments of the present disclosure, the fusion protein comprises a Cas13 protein or a functional fragment thereof as described herein fused to a homologous or heterologous protein domain and / or a polypeptide tag. In some embodiments, the fusion does not change the original function of the Cas13 protein and / or its functional fragment.

[0121] The original function of the Cas13 protein or its functional fragment that is not changed refers to the fused protein still having the ability to identify, bind and / or cut the target RNA when used in combination with gRNA. The ability of the fused protein to identify, bind or cut the target RNA when used in combination with gRNA may be improved or reduced compared to the ability of the Cas13 protein to identify, bind or cut the target RNA when used in combination with gRNA, but as long as the fused protein can effectively identify, bind or cut the target RNA when used in combination with gRNA, it all belongs to the case of "not changing the original function of the Cas13 protein".

[0122] In some embodiments, the fusion protein comprises a Cas13 protein described herein fused to a homologous or heterologous protein domain and / or a polypeptide tag. In some embodiments, the fusion protein comprises a functional fragment of a Cas13 protein described herein fused to a homologous or heterologous protein domain and / or a polypeptide tag. For example, in some embodiments, the functional fragment is a fragment obtained by deleting a portion of the sequence of the nuclease domain of the Cas13 protein. In some embodiments, the functional fragment is a fragment obtained by deleting a sequence corresponding to HEPN-1_Ⅰ, HEPN-1_Ⅱ, HEPN-2, NTD, Helical-1 and / or Helical-2 of C13-2 from the Cas13 protein. In some embodiments, the functional fragment is a fragment obtained by deleting a sequence corresponding to HEPN-1_Ⅰ, HEPN-1_Ⅱ and / or HEPN-2 of C13-2 from the Cas13 protein. In some embodiments, the functional fragment is a fragment obtained by deleting a sequence corresponding to HEPN-1_Ⅰ, HEPN-1_Ⅱ and / or HEPN-2 of C13-2 from the Cas13 protein. In some embodiments, the functional fragment is a fragment obtained by deleting the sequence corresponding to HEPN-1_II of C13-2 from the Cas13 protein. In some embodiments, the functional fragment is a fragment obtained by deleting the sequence corresponding to HEPN-2 of C13-2 from the Cas13 protein. In some embodiments, the functional fragment is a fragment obtained by deleting the sequence corresponding to NTD and HEPN-1_I of C13-2 from the Cas13 protein.

[0123] In some embodiments, the Cas13 protein or a functional fragment thereof is fused to any one or more selected from the group consisting of a cytosine deaminase domain, an adenosine deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter domain, an affinity domain, a subcellular localization signal, a reporter tag, and an affinity tag.

[0124] In some embodiments, the Cas13 protein or its functional fragment fusion subcellular localization signal.In some embodiments, the subcellular localization signal is optionally selected from nuclear localization signal (NLS), nuclear export signal (NES), chloroplast localization signal or mitochondrial localization signal.

[0125] In some embodiments, the Cas13 protein or a functional fragment thereof is fused to any one or more selected from the group consisting of a cytosine deaminase domain, an adenosine deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter domain, an affinity domain, a subcellular localization signal, a reporter tag, and an affinity tag.

[0126] In some embodiments, the Cas13 protein or its functional fragment fusion subcellular localization signal.In some embodiments, the subcellular localization signal is optionally selected from nuclear localization signal (NLS), nuclear export signal (NES), chloroplast localization signal or mitochondrial localization signal.

[0127] In some embodiments, the Cas13 protein or its functional fragment is fused to a homologous or heterologous nuclear localization signal (NLS). In some embodiments, the Cas13 protein or its functional fragment is fused to a homologous or heterologous nuclear export signal (NES).

[0128] In some embodiments, the Cas13 protein or its functional fragment is covalently linked to the protein domain and / or polypeptide tag. In some embodiments, the Cas13 protein or its functional fragment is directly covalently linked to the protein domain and / or polypeptide tag. In some embodiments, the Cas13 protein or its functional fragment is covalently linked to the protein domain and / or polypeptide tag via a linker sequence; further, in some embodiments, the linker sequence is an amino acid sequence.

[0129] In some embodiments, the Cas13 protein of the fusion protein or its functional fragment is connected to the homologous or heterologous protein domain and / or polypeptide tag by a rigid connection peptide sequence. In some embodiments, the Cas13 protein portion of the fusion protein is connected to the homologous or heterologous protein domain and / or polypeptide tag by a flexible connection peptide sequence. In some embodiments, the rigid connection peptide sequence is A(EAAAK)3A (SEQ ID NO: 279). In some embodiments, the flexible connection peptide sequence is (GGGGS)3 (SEQ ID NO: 280).

[0130] In some embodiments, the fusion protein is capable of forming a CRISPR complex with a guide polynucleotide, and the CRISPR complex can specifically bind to a target RNA sequence. In some embodiments, the fusion protein comprises a Cas13 protein as described herein fused to a homologous or heterologous protein domain and / or a polypeptide tag, and the fusion protein is capable of forming a CRISPR complex with a guide polynucleotide, and the CRISPR complex can specifically bind to a target RNA sequence. In some embodiments, the fusion protein comprises a functional fragment of a Cas13 protein as described herein fused to a homologous or heterologous protein domain and / or a polypeptide tag, and the fusion protein is capable of forming a CRISPR complex with a guide polynucleotide, and the CRISPR complex can specifically bind to a target RNA sequence.

[0131] In some embodiments, the fusion protein is capable of forming a CRISPR complex with a guide polynucleotide, the guide polynucleotide comprising a direct repeat sequence connected to a guide sequence, and the guide sequence is engineered to guide the sequence-specific binding of the CRISPR complex to the target RNA. In some embodiments, the fusion protein comprises the Cas13 protein as described herein fused to a homologous or heterologous protein domain and / or a polypeptide tag, the fusion protein is capable of forming a CRISPR complex with a guide polynucleotide, the guide polynucleotide comprising a direct repeat sequence connected to a guide sequence, and the guide sequence is engineered to guide the sequence-specific binding of the CRISPR complex to the target RNA. In some embodiments, the fusion protein comprises a functional fragment of the Cas13 protein as described herein fused to a homologous or heterologous protein domain and / or a polypeptide tag, the fusion protein is capable of forming a CRISPR complex with a guide polynucleotide, the guide polynucleotide comprising a direct repeat sequence connected to a guide sequence, and the guide sequence is engineered to guide the sequence-specific binding of the CRISPR complex to the target RNA.

[0132] In some embodiments, the fusion protein is capable of forming a CRISPR complex with a guide polynucleotide, and the CRISPR complex can sequence-specifically bind to and cut the target RNA. In some embodiments, the fusion protein comprises the Cas13 protein described herein fused to a homologous or heterologous protein domain and / or a polypeptide tag, and the fusion protein is capable of forming a CRISPR complex with a guide polynucleotide, and the CRISPR complex can specifically bind to a target RNA sequence. In some embodiments, the fusion protein comprises a functional fragment of the Cas13 protein described herein fused to a homologous or heterologous protein domain and / or a polypeptide tag, and the fusion protein is capable of forming a CRISPR complex with a guide polynucleotide, and the CRISPR complex can specifically bind to a target RNA sequence.

[0133] In some embodiments, the structure of the fusion protein is NLS-Cas13 protein-SV40NLS-nucleoplasmin NLS.

[0134] Another aspect of the present disclosure relates to a guide polynucleotide comprising (i) a direct repeat sequence having at least 50% sequence identity to any one of SEQ ID NO: 3 and SEQ ID NO: 80-87, linked to (ii) a homologous or heterologous guide sequence engineered to hybridize to a target RNA, wherein the guide polynucleotide is capable of forming a CRISPR complex with a Cas13 protein and directing sequence-specific binding of the CRISPR complex to the target RNA.

[0135] In some embodiments, the Cas13 protein is Cas13a, Cas13b, Cas13c or Cas13d. In some embodiments, the amino acid sequence of the Cas13 protein has a sequence identity of at least 90%, at least 95%, at least 98% or at least 99% compared to SEQ ID NO: 1.

[0136] In some embodiments, the direct repeat sequence has at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity compared to SEQ ID NO: 3 and any one of SEQ ID NOs: 80-87. In some embodiments, the direct repeat sequence has at least 80% sequence identity compared to SEQ ID NO: 3 and any one of SEQ ID NOs: 80-87. In some embodiments, the direct repeat sequence has at least 85% sequence identity compared to SEQ ID NO: 3 and any one of SEQ ID NOs: 80-87. In some embodiments, the direct repeat sequence has at least 90% sequence identity compared to SEQ ID NO: 3 and any one of SEQ ID NOs: 80-87. In some embodiments, the direct repeat sequence has at least 95% sequence identity compared to SEQ ID NO: 3 and any one of SEQ ID NOs: 80-87. In some embodiments, the direct repeat sequence has 100% sequence identity compared to SEQ ID NO: 3 and any one of SEQ ID NOs: 80-87.

[0137] In some embodiments, the direct repeat sequence has at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity compared to any one of SEQ ID NOs: 3, 81, 82, 84 and 87.

[0138] In some embodiments, the direct repeat sequence has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity compared to any of SEQ ID NOs: 3 and 87.

[0139] In some embodiments, the direct repeat sequence is A at base 26 corresponding to SEQ ID NO: 3.

[0140] In some embodiments, the direct repeat sequence is GGAAGATN1ACTCTACAAACCTGTAGN2GN3N4N5N6N7N8N9N 10 N 11 (SEQ ID NO: 277); wherein N1 and N3-N 11 Any one selected from A, C, G, T; N2 any one selected from A and G.

[0141] In some embodiments, the direct repeat sequence is GGAAGATN 12 ACTCTACAAACCTGTAGN 13 GN 14 N 15 N 16 N 17 N 18 N 19 N 20 N 21 N 22 (SEQ ID NO: 278); wherein N 12 、N 13 、N 19 and N 21 Any one selected from A, G, N 14 Any one selected from A, T, N 15 and N 16 Any one selected from C, T, N 17 and N 18 Any one of G, T, N 20 and N 22 Any one selected from C and G.

[0142] In some embodiments, the guide sequence is located at the 3' end of the direct repeat sequence. In some embodiments, the guide sequence is located at the 5' end of the direct repeat sequence.

[0143] In some embodiments, the guide sequence comprises 15-35 nucleotides. In some embodiments, the guide sequence hybridizes to the target RNA with no more than one nucleotide mismatch. In some embodiments, the direct repeat sequence comprises 25 to 40 nucleotides.

[0144] In some embodiments, the guide polynucleotide further comprises an aptamer sequence. In some embodiments, the aptamer sequence is inserted into the loop of the guide polynucleotide. In some embodiments, the aptamer sequence comprises an MS2 aptamer sequence, a PP7 aptamer sequence, or a Qβ aptamer sequence.

[0145] In some embodiments, the guide polynucleotide comprises modified nucleotides. In some embodiments, the modification comprises 2'-O-methyl, 2'-O-methyl-3'-phosphorothioate, or 2'-O-methyl-3'-thioPACE.

[0146] In some embodiments, the target RNA of the guide polynucleotide is located in the nucleus of a eukaryotic cell.

[0147] In some embodiments, the target RNA is selected from TTR RNA, SOD1 RNA, PCSK9 RNA, VEGFA RNA, VEGFR1 RNA, PTBP1 RNA, AQp1 RNA, or ANGPTL3 RNA. Alternatively, in some embodiments, the target RNA is selected from VEGFA RNA, PTBP1 RNA, AQp1 RNA, or ANGPTL3 RNA. Further, the guide sequence is selected from the sequences shown in SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NOs: 42-49 (for targeting AQp1 RNA, PTBP1 RNA, and ANGPTL3 RNA, respectively). Preferably, the guide sequence is selected from the sequences shown in SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 43, and SEQ ID NOs: 45-47.

[0148] In some embodiments, the Cas13 protein is Cas13a, Cas13b, Cas13c, or Cas13d. In some embodiments, the Cas13 protein is Cas13d. In some embodiments, the Cas13 protein has a sequence identity of at least 90%, at least 95%, at least 98%, or at least 99% compared to SEQ ID NO: 1.

[0149] Another aspect of the present disclosure relates to a CRISPR-Cas13 system, comprising: a Cas13 protein or fusion protein as described herein, or a nucleic acid encoding the Cas13 protein or fusion protein; and a guide polynucleotide or a nucleic acid encoding the guide polynucleotide; the guide polynucleotide comprises a direct repeat sequence linked to a guide sequence, the guide sequence being engineered to hybridize with a target RNA; the guide polynucleotide is capable of forming a CRISPR complex with the Cas13 protein or fusion protein and guiding the CRISPR complex to sequence-specific binding to the target RNA.

[0150] In some embodiments, the target RNA is selected from TTR RNA, SOD1 RNA, PCSK9 RNA, VEGFA RNA, VEGFR1 RNA, PTBP1 RNA, AQp1 RNA, or ANGPTL3 RNA. Alternatively, in some embodiments, the target RNA is selected from VEGFA RNA, PTBP1 RNA, AQp1 RNA, or ANGPTL3 RNA. In some embodiments, the guide sequence is selected from the sequences shown in SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NOs: 42-49 (for targeting AQp1 RNA, PTBP1 RNA, and ANGPTL3 RNA, respectively). In some embodiments, the guide sequence is selected from the sequences shown in SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 43, and SEQ ID NOs: 45-47.

[0151] In some embodiments, the direct repeat sequence has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity compared to any one of SEQ ID NOs: 3, 81, 82, 84 and 87.

[0152] In some embodiments, the fusion protein comprises a Cas13 protein described herein or a functional fragment thereof fused to a homologous or heterologous protein domain and / or polypeptide tag.

[0153] In some embodiments, the Cas13 protein of the fusion protein or its functional fragment portion is fused to a homologous or heterologous nuclear localization signal (NLS). In some embodiments, the Cas13 protein of the fusion protein or its functional fragment portion is fused to a homologous or heterologous nuclear export signal (NES).

[0154] In some embodiments, the Cas13 protein comprises a mutation in the catalytic domain and has reduced RNA cleavage activity. In some embodiments, the Cas13 protein comprises a mutation in one or both HEPN domains and substantially lacks RNA cleavage activity. In some embodiments, the “substantially lacking RNA cleavage activity” refers to retaining only ≤50%, ≤40%, ≤30%, ≤20%, ≤10%, ≤5% or ≤1% RNA cleavage activity compared to the wild-type Cas13 protein, or no detectable RNA cleavage activity.

[0155] In some embodiments, the Cas13 protein of the fusion protein or its functional fragment portion is directly connected to the homologous or heterologous protein domain and / or polypeptide tag through a covalent bond. In some embodiments, the Cas13 protein portion of the fusion protein is connected to the homologous or heterologous protein domain and / or polypeptide tag through a peptide sequence.

[0156] In some embodiments, the protein domain comprises a cytosine deaminase domain, an adenosine deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, or a splicing factor domain. In some embodiments, the Cas13 protein is covalently linked to an affinity tag or a reporter tag.

[0157] In some embodiments, the Cas13 protein has at least 95% sequence identity compared to SEQ ID NO: 1. In some embodiments, the Cas13 protein has at least 97% sequence identity compared to SEQ ID NO: 1. In some embodiments, the Cas13 protein has at least 98% sequence identity compared to SEQ ID NO: 1. In some embodiments, the Cas13 protein has at least 99% sequence identity compared to SEQ ID NO: 1. In some embodiments, the Cas13 protein has at least 99.5% sequence identity compared to SEQ ID NO: 1. In some embodiments, the Cas13 protein comprises the sequence shown in SEQ ID NO: 1.

[0158] In some embodiments, the Cas13 protein is from a species comprising a genome with an average nucleotide identity (ANI) ≥ 95% to the genome numbered CNA0009596 in the CNGB database.

[0159] In some embodiments, the Cas13 protein is used for RNA cleavage without the requirement for a protospacer flanking sequence (PFS).

[0160] In some embodiments, the guide sequence is located at the 3' end of the direct repeat sequence. In some embodiments, the guide sequence is located at the 5' end of the direct repeat sequence.

[0161] In some embodiments, the guide sequence comprises 15-35 nucleotides.In some embodiments, the guide sequence hybridizes to the target RNA with no more than one nucleotide mismatch.

[0162] In some embodiments, the direct repeat sequence comprises 25 to 40 nucleotides.

[0163] In some embodiments, the direct repeat sequence has at least 80% sequence identity compared to SEQ ID NO: 3 and any one of SEQ ID NOs: 80-87. In some embodiments, the direct repeat sequence has at least 90% sequence identity compared to SEQ ID NO: 3 and any one of SEQ ID NOs: 80-87. In some embodiments, the direct repeat sequence has at least 95% sequence identity compared to SEQ ID NO: 3 and any one of SEQ ID NOs: 80-87. In some embodiments, the direct repeat sequence has 100% sequence identity compared to SEQ ID NO: 3 and any one of SEQ ID NOs: 80-87. In some embodiments, the direct repeat sequence is optionally selected from SEQ ID NO: 3 and SEQ ID NOs: 80-87.

[0164] In some embodiments, the guide polynucleotide further comprises an aptamer sequence. In some embodiments, the aptamer sequence is inserted into the loop of the guide polynucleotide. In some embodiments, the aptamer sequence comprises an MS2 aptamer sequence, a PP7 aptamer sequence, or a Qβ aptamer sequence.

[0165] In some embodiments, the CRISPR-Cas13 system includes a fusion protein comprising an adaptor protein and a homologous or heterologous protein domain, or a nucleic acid encoding the fusion protein, wherein the adaptor protein is capable of binding to the adaptor sequence.

[0166] In some embodiments, the adaptor protein comprises an MS2 phage coat protein, a PP7 phage coat protein, or a Qβ phage coat protein. In some embodiments, the protein domain comprises a cytosine deaminase domain, an adenosine deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter domain, an affinity domain, a reporter tag, and an affinity tag.

[0167] In some embodiments, the guide polynucleotide comprises modified nucleotides. In some embodiments, the modified nucleotides comprise 2'-O-methyl, 2'-O-methyl-3'-phosphorothioate, or 2'-O-methyl-3'-thioPACE.

[0168] In some embodiments, the Cas13 protein or fusion protein and the guide polynucleotide do not naturally co-exist.

[0169] Another aspect of the present disclosure relates to a CRISPR-Cas13 system, characterized in that it comprises any one Cas13 protein, its fusion protein or a nucleic acid encoding the same, and a guide polynucleotide described herein or a nucleic acid encoding the same.

[0170] Another aspect of the present disclosure relates to a vector system comprising a CRISPR-Cas13 system as described herein, comprising one or more vectors comprising a polynucleotide sequence encoding a Cas13 protein or fusion protein as described herein and a polynucleotide sequence encoding a guide polynucleotide.

[0171] Another aspect of the present disclosure relates to an adeno-associated virus (AAV) vector comprising the CRISPR-Cas13 system described herein, wherein the AAV vector comprises a DNA sequence encoding the Cas13 protein or fusion protein described herein and the guide polynucleotide.

[0172] Another aspect of the present disclosure relates to lipid nanoparticles comprising a CRISPR-Cas13 system described herein, comprising a guide polynucleotide described herein and an mRNA encoding a Cas13 protein or fusion protein described herein.

[0173] Another aspect of the present disclosure relates to a lentiviral vector comprising a CRISPR-Cas13 system as described herein, comprising a guide polynucleotide as described herein and an mRNA encoding a Cas13 protein or fusion protein as described herein. In some embodiments, the lentiviral vector is pseudotyped with a homologous or heterologous envelope protein such as VSV-G. In some embodiments, the mRNA encoding the Cas13 protein or fusion protein is linked to an aptamer sequence.

[0174] Another aspect of the present disclosure relates to a ribonucleoprotein complex comprising a CRISPR-Cas13 system described herein, wherein the ribonucleoprotein complex is formed by a guide polynucleotide described herein and a Cas13 protein or fusion protein described herein.

[0175] Another aspect of the present disclosure relates to virus-like particles comprising a CRISPR-Cas13 system as described herein, comprising a ribonucleoprotein complex formed by a guide polynucleotide as described herein and a Cas13 protein or fusion protein as described herein. In some embodiments, the Cas13 protein or fusion protein is fused to a gag protein.

[0176] Another aspect of the present disclosure relates to eukaryotic cells comprising the CRISPR-Cas13 system described herein. In some embodiments, the eukaryotic cells are mammalian cells. In some embodiments, the eukaryotic cells are human cells.

[0177] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a CRISPR-Cas13 system described herein, a Cas13 protein described herein, a fusion protein described herein, a guide polynucleotide described herein, a nucleic acid described herein, a vector system described herein, a lipid nanoparticle described herein, a lentiviral vector described herein, a ribonucleoprotein complex described herein, a virus-like particle described herein, or a eukaryotic cell described herein.

[0178] Another aspect of the present disclosure relates to a pharmaceutical composition comprising the CRISPR-Cas13 system described herein.

[0179] Another aspect of the present disclosure relates to an in vitro composition comprising a CRISPR-Cas13 system described herein, and a labeled detector RNA that is incapable of hybridizing to or being targeted by a guide polynucleotide described herein.

[0180] Another aspect of the present disclosure relates to an isolated nucleic acid encoding a Cas13 protein or fusion protein described herein.

[0181] Another aspect of the disclosure relates to isolated nucleic acids encoding the guide polynucleotides described herein.

[0182] Another aspect of the present disclosure relates to a CRISPR-Cas13 system comprising any one of the Cas13 proteins or nucleic acids encoding the same, and a guide polynucleotide described herein or an isolated nucleic acid encoding the same.

[0183] Another aspect of the present disclosure relates to the use of the CRISPR-Cas13 system described herein in detecting a target RNA in a nucleic acid sample suspected of containing the target RNA or in preparing a reagent for detecting a target RNA in a nucleic acid sample suspected of containing the target RNA.

[0184] Another aspect of the present disclosure relates to the use of a CRISPR-Cas13 system as described herein, a Cas13 protein as described herein, a fusion protein as described herein, a guide polynucleotide as described herein, a nucleic acid as described herein, a vector system as described herein, a lipid nanoparticle as described herein, a lentiviral vector as described herein, a ribonucleoprotein complex as described herein, a virus-like particle as described herein, or a eukaryotic cell as described herein in any of the following or in the preparation of a reagent for achieving any of the following schemes:

[0185] Cleave or nick one or more target RNA molecules, activate or upregulate one or more target RNA molecules, activate or inhibit translation of one or more target RNA molecules, inactivate one or more target RNA molecules, visualize, label or detect one or more target RNA molecules, bind one or more target RNA molecules, transport one or more target RNA molecules, and mask one or more target RNA molecules.

[0186] Another aspect of the present disclosure relates to the use of a CRISPR-Cas13 system as described herein, a Cas13 protein as described herein, a fusion protein as described herein, a guide polynucleotide as described herein, a nucleic acid as described herein, a vector system as described herein, a lipid nanoparticle as described herein, a lentiviral vector as described herein, a ribonucleoprotein complex as described herein, a virus-like particle as described herein, or a eukaryotic cell as described herein in cleaving one or more target RNA molecules or preparing an agent for cleaving one or more target RNA molecules.

[0187] Another aspect of the present disclosure relates to a method comprising using a CRISPR-Cas13 system as described herein, a Cas13 protein as described herein, a fusion protein as described herein, a guide polynucleotide as described herein, a nucleic acid as described herein, a vector system as described herein, a lipid nanoparticle as described herein, a lentiviral vector as described herein, a ribonucleoprotein complex as described herein, a virus-like particle as described herein, or a eukaryotic cell as described herein to bind one or more target RNA molecules.

[0188] Another aspect of the present disclosure relates to the use of the CRISPR-Cas13 system described herein in the preparation of a reagent that binds to or cleaves one or more target RNA molecules.

[0189] Another aspect of the present disclosure relates to the use of a CRISPR-Cas13 system as described herein, a Cas13 protein as described herein, a fusion protein as described herein, a guide polynucleotide as described herein, a nucleic acid as described herein, a vector system as described herein, a lipid nanoparticle as described herein, a lentiviral vector as described herein, a ribonucleoprotein complex as described herein, a virus-like particle as described herein, or a eukaryotic cell as described herein for cutting or editing a target RNA in a mammalian cell, wherein the editing is base editing.

[0190] Another aspect of the present disclosure relates to the use of the CRISPR-Cas13 system described herein in preparing a reagent for cutting or editing a target RNA in a mammalian cell, wherein the editing is base editing.

[0191] Another aspect of the present disclosure relates to the use of a CRISPR-Cas13 system as described herein, a Cas13 protein as described herein, a fusion protein as described herein, a guide polynucleotide as described herein, a nucleic acid as described herein, a vector system as described herein, a lipid nanoparticle as described herein, a lentiviral vector as described herein, a ribonucleoprotein complex as described herein, a virus-like particle as described herein, or a eukaryotic cell as described herein in activating or upregulating one or more target RNA molecules or in preparing an agent that activates or upregulates one or more target RNA molecules.

[0192] Another aspect of the present disclosure relates to the use of a CRISPR-Cas13 system as described herein, a Cas13 protein as described herein, a fusion protein as described herein, a guide polynucleotide as described herein, a nucleic acid as described herein, a vector system as described herein, a lipid nanoparticle as described herein, a lentiviral vector as described herein, a ribonucleoprotein complex as described herein, a virus-like particle as described herein, or a eukaryotic cell as described herein in inhibiting the translation of one or more target RNA molecules or in the preparation of an agent for inhibiting the translation of one or more target RNA molecules.

[0193] Another aspect of the present disclosure relates to the use of a CRISPR-Cas13 system as described herein, a Cas13 protein as described herein, a fusion protein as described herein, a guide polynucleotide as described herein, a nucleic acid as described herein, a vector system as described herein, a lipid nanoparticle as described herein, a lentiviral vector as described herein, a ribonucleoprotein complex as described herein, a virus-like particle as described herein, or a eukaryotic cell as described herein in inactivating one or more target RNA molecules or in preparing an agent that inactivates one or more target RNA molecules.

[0194] Another aspect of the present disclosure relates to the use of a CRISPR-Cas13 system described herein, a Cas13 protein described herein, a fusion protein described herein, a guide polynucleotide described herein, a nucleic acid described herein, a vector system described herein, a lipid nanoparticle described herein, a lentiviral vector described herein, a ribonucleoprotein complex described herein, a virus-like particle described herein, or a eukaryotic cell described herein in visualizing, labeling, or detecting one or more target RNA molecules or in preparing a reagent for visualizing, labeling, or detecting one or more target RNA molecules.

[0195] Another aspect of the present disclosure relates to the use of a CRISPR-Cas13 system as described herein, a Cas13 protein as described herein, a fusion protein as described herein, a guide polynucleotide as described herein, a nucleic acid as described herein, a vector system as described herein, a lipid nanoparticle as described herein, a lentiviral vector as described herein, a ribonucleoprotein complex as described herein, a virus-like particle as described herein, or a eukaryotic cell as described herein in transporting one or more target RNA molecules or preparing an agent for transporting one or more target RNA molecules.

[0196] Another aspect of the present disclosure relates to the use of a CRISPR-Cas13 system as described herein, a Cas13 protein as described herein, a fusion protein as described herein, a guide polynucleotide as described herein, a nucleic acid as described herein, a vector system as described herein, a lipid nanoparticle as described herein, a lentiviral vector as described herein, a ribonucleoprotein complex as described herein, a virus-like particle as described herein, or a eukaryotic cell as described herein in masking one or more target RNA molecules or in preparing an agent for masking one or more target RNA molecules.

[0197] Another aspect of the present disclosure relates to the use of a CRISPR-Cas13 system described herein, a Cas13 protein described herein, a fusion protein described herein, a guide polynucleotide described herein, a nucleic acid described herein, a vector system described herein, a lipid nanoparticle described herein, a lentiviral vector described herein, a ribonucleoprotein complex described herein, a virus-like particle described herein, or a eukaryotic cell described herein in the diagnosis, treatment, or prevention of a disease or disorder associated with a target RNA.

[0198] Another aspect of the present disclosure relates to the use of the CRISPR-Cas13 system described herein in the diagnosis, treatment, or prevention of a disease or disorder associated with a target RNA.

[0199] Another aspect of the present disclosure relates to a method for diagnosing, treating or preventing a disease or condition associated with a target RNA, the method comprising administering a Cas13 protein as described herein, a fusion protein as described herein, a guide polynucleotide as described herein, a CRISPR-Cas13 system as described herein, or an isolated nucleic acid as described herein to a sample of a subject in need thereof or to a subject in need thereof.

[0200] Another aspect of the present disclosure relates to the use of a CRISPR-Cas13 system described herein, a Cas13 protein described herein, a fusion protein described herein, a guide polynucleotide described herein, a nucleic acid described herein, a vector system described herein, a lipid nanoparticle described herein, a lentiviral vector described herein, a ribonucleoprotein complex described herein, a virus-like particle described herein, or a eukaryotic cell described herein in the preparation of a medicament for diagnosing, treating, or preventing a disease or condition associated with a target RNA.

[0201] Another aspect of the present disclosure relates to the use of the CRISPR-Cas13 system described herein in the preparation of a medicament for diagnosing, treating, or preventing a disease or condition associated with a target RNA. The above preferred conditions may be arbitrarily combined, consistent with common sense in the art, to obtain preferred embodiments of the present disclosure.

[0202] The reagents and raw materials used in this disclosure are commercially available. BRIEF DESCRIPTION OF THE DRAWINGS

[0203] FIG1 shows the CRISPR locus of the CRISPR-Cas13 system, including the CRISPR array and the coding sequence of the C13-2 protein.

[0204] Figure 2 shows the structure of the C13-2 guide polynucleotide, which consists of a direct repeat sequence and a guide sequence. In this figure, the backbone sequence is the same as the direct repeat sequence; the guide sequence is composed of a variable number of nucleotides, where N represents an arbitrary nucleotide. The direct repeat sequence (SEQ ID NO: 3) was predicted using RNAfold to obtain its secondary structure, as shown in the figure, showing a stem-loop structure, with the stem region containing multiple complementary base pairs.

[0205] FIG3 shows the expression and purification of recombinant C13-2 protein.

[0206] FIG4 shows that C13-2 is highly active in downregulating PTBP1 (polypyrimidine tract binding protein 1) RNA in 293T cells.

[0207] FIG5 shows that C13-2 has higher activity in downregulating AQp1 (aquaporin 1) RNA in 293T cells compared to CasRx and shRNA.

[0208] Figure 6 shows that C13-2 has higher activity in downregulating PTBP1 RNA in 293T cells compared to C13-113 and C13-114.

[0209] FIG7 shows that C13-2 can downregulate ANGPTL3 (angiopoietin-like 3) RNA in 293T cells.

[0210] Figure 8 shows the C13-2 domain predicted by the computational method; in the figure, positions 1-95 are the NTD domain, positions 96-255 are the HEPN-1_Ⅰ domain, positions 256-417 are the Helical-1 domain, positions 418-504 are the HEPN-1_Ⅱ domain, positions 505-651 are the Helical-2 domain, and positions 652-893 are the HEPN-2 domain.

[0211] FIG9 shows the editing effect of targeting VEGFA RNA using different DRs.

[0212] FIG10 shows the editing effect of targeting PTBP1 RNA using different DRs.

[0213] Figure 11 shows a comparison of the effects of C13-2 and known Cas13 tools targeting VEGFA RNA.

[0214] Figure 12 shows a comparison of the effectiveness of C13-2 and known Cas13 tools in targeting PTBP1 RNA.

[0215] FIG13 shows the sequencing peak graph after single-base editing of dC13-2.

[0216] FIG14 shows qPCR testing of VEGFA RNA levels after targeted editing of mutants.

[0217] FIG15 shows VEGFA RNA levels after editing tested by RNAseq.

[0218] FIG16 shows the editing efficiency of AR RNA by mutants tested by qPCR.

[0219] FIG17 shows the AR RNA levels after editing as measured by RNAseq.

[0220] FIG18 shows the sequence alignment results of the direct repeat sequences DRrc, DR-hf2, and DR2rc.

[0221] FIG19 shows the RNA secondary structure of the direct repeat sequence DR-hf2 (SEQ ID NO: 87) predicted by RNAfold. DETAILED DESCRIPTION

[0222] The present disclosure is further illustrated by way of examples below, but the present disclosure is not limited to the scope of the examples. Experimental methods in the following examples without specifying specific conditions were performed according to conventional methods and conditions, or selected according to the product specifications.

[0223] As used herein, the term "sequence identity" (identity or percent identity) is used to refer to the matching of sequences between two polypeptides or between two nucleic acids. When a certain position in the two sequences being compared is occupied by the same base or amino acid monomer subunit (for example, a certain position in each of the two DNA molecules is occupied by adenine, or a certain position in each of the two polypeptides is occupied by lysine), then the molecules are identical at that position. The "percent sequence identity" (percent identity) between two sequences is a function of the number of matching positions shared by the two sequences divided by the number of positions compared × 100%. For example, if 6 out of 10 positions in two sequences match, then the two sequences have 60% sequence identity. Typically, comparisons are made when two sequences are aligned to produce maximum sequence identity. Such comparisons can be performed using published and commercially available alignment algorithms and programs, such as, but not limited to, ClustalΩ, MAFFT, Probcons, T-Coffee, Probalign, BLAST, which can be reasonably selected by one of ordinary skill in the art. Those skilled in the art can determine appropriate parameters for aligning sequences, including, for example, any algorithms needed to achieve better alignment or optimal comparison over the entire length of the sequences being compared, as well as any algorithms needed to achieve better alignment or optimal comparison over a portion of the sequences being compared.

[0224] As used herein, the term "guide polynucleotide" is used to refer to a molecule in the CRISPR-Cas system that forms a CRISPR complex with the Cas protein and guides the CRISPR complex to the target sequence. Typically, the guide polynucleotide comprises a backbone sequence connected to a guide sequence, and the guide sequence can hybridize with the target sequence. The backbone sequence typically comprises a direct repeat sequence and sometimes may further comprise a tracrRNA sequence. When the backbone sequence does not comprise a tracrRNA sequence, the guide polynucleotide comprises a guide sequence and a direct repeat sequence, and the guide polynucleotide may also be referred to as crRNA.

[0225] CRISPR-Cas13 system

[0226] Class 2 CRISPR-Cas systems confer diverse adaptive immunity mechanisms to microorganisms. Here, we present analyses of prokaryotic genomes and metagenomes to identify a previously uncharacterized RNA-guided, RNA-targeting CRISPR-Cas13 system comprising C13-2 (also known as CasRfg.4), which is classified as a Type VI system. Engineered CRISPR-Cas13 systems based on C13-2 exhibit robust activity in human cells. As a compact, single-effector Cas13 enzyme, C13-2 can also be flexibly packaged into AAV vectors. Our results demonstrate the use of C13-2 as a programmable RNA-binding module for efficient targeting of cellular RNAs, providing a versatile platform for transcriptome engineering as well as therapeutic and diagnostic approaches.

[0227] As described in Experimental Example 1, based on bioinformatics analysis of prokaryotic genomes and metagenomes in the NCBI GenBank and CNGB databases, a CRISPR-Cas13 system comprising C13-2 was identified, and the targeted RNA cleavage activity in human cells was subsequently experimentally verified. The CRISPR-Cas13 system comprising C13-2 is a type VI CRISPR-Cas system. Figure 1 shows the CRISPR locus of the CRISPR-Cas13 system comprising C13-2. The protein sequence of wild-type C13-2 is SEQ ID NO: 1. The wild-type DNA coding sequence of C13-2 is SEQ ID NO: 9. Figure 8 shows the computationally predicted domain structure of C13-2, which includes NTD, HEPN-1_I, HEPN-1_Ⅱ and HEPN-2, NTD is the N terminus domain, and between HEPN-1_I and HEPN-1_Ⅱ, and between HEPN-1_Ⅱ and HEPN-2, respectively, the Helical-1 and Helical-2 domains. The direct repeat sequence of the C13-2 guide polynucleotide is SEQ ID NO: 3. Figure 2 shows the RNA secondary structure of the direct repeat sequence of the C13-2 guide polynucleotide predicted by RNAfold. The engineered CRISPR-Cas13 system described herein can effectively knock down endogenous target RNAs in human cells, paving the way for RNA-targeted applications as part of the transcriptome engineering toolbox. In some embodiments, C13-2-mediated knockdown across multiple endogenous transcripts can achieve higher efficiency and / or specificity than knockdown mediated by CasRx, PspCas13b, Cas13X.1 and / or Cas13Y.1.

[0228] Therefore, one aspect of the present disclosure relates to a CRISPR-Cas13 system, composition or kit comprising: a Cas13 protein or fusion protein having at least 90% sequence identity to SEQ ID NO: 1, or a nucleic acid encoding the Cas13 protein; and a guide polynucleotide or a nucleic acid encoding the guide polynucleotide; the guide polynucleotide comprising a direct repeat sequence connected to a guide sequence, the guide sequence being engineered to hybridize with a target RNA, the guide polynucleotide being capable of forming a CRISPR complex with the Cas13 protein and guiding the sequence-specific binding of the CRISPR complex to the target RNA.

[0229] In some embodiments, the guide polynucleotide comprises a direct repeat sequence connected to a guide sequence, the guide sequence being engineered to hybridize with a target RNA, the guide polynucleotide being capable of forming a CRISPR complex with the Cas13 protein and directing the CRISPR complex sequence to specifically bind to and cleave the target RNA.

[0230] In some embodiments, the polynucleotide sequence encoding the Cas13 protein or fusion protein and / or the polynucleotide sequence encoding the guide polynucleotide is operably connected to a regulatory sequence. In some embodiments, the polynucleotide sequence encoding the Cas13 protein or fusion protein is operably connected to a regulatory sequence. In some embodiments, the polynucleotide sequence encoding the guide polynucleotide is operably connected to a regulatory sequence. In some embodiments, the regulatory sequence of the polynucleotide sequence encoding the Cas13 protein or fusion protein is the same as or different from the regulatory sequence of the polynucleotide sequence encoding the guide polynucleotide.

[0231] In some embodiments, the Cas13 proteins described herein have at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity compared to SEQ ID NO: 1. In some embodiments, the Cas13 proteins described herein have at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity compared to the protein sequence encoded by SEQ ID NO: 9. When the CRISPR-Cas13 system includes a fusion protein comprising the Cas13 protein and a protein domain and / or a polypeptide tag, the percentage of sequence identity between the Cas13 portion of the fusion protein and the reference sequence is calculated.

[0232] In some embodiments, the Cas13 protein described herein is from a species comprising a genome having an average nucleotide identity (ANI) ≥ 95% with the genome shown in the CNGB database as CNA0009596.

[0233] In some embodiments, the Cas13 protein described herein comprises one or more (e.g., 1 or 2) native HEPN domains, each native HEPN domain comprising an RX4H amino acid motif (wherein X represents any amino acid, and the subscript "4" represents 4 consecutive amino acids). In some embodiments, the first catalytic RX4H motif is located at amino acid positions 210-215 of SEQ ID NO: 1, the second catalytic RX4H motif is located at amino acid positions 785-790 of SEQ ID NO: 1, and the third RX4H motif is located at amino acid positions 750-755 of SEQ ID NO: 1. In some embodiments, the Cas13 protein described herein comprises one or more mutated HEPN domains. In some embodiments, the mutant Cas13 protein can process its guide polynucleotide but cannot cut the target RNA.

[0234] In some embodiments, the Cas13 protein described herein is used for RNA cleavage without the requirement for a protospacer flanking sequence (PFS).

[0235] The CRISPR-Cas13 system described herein can be introduced into a cell (or cell-free system) in a variety of non-limiting ways: (i) as Cas13 mRNA and a guide polynucleotide, (ii) as part of a single vector or plasmid, or divided into multiple vectors or plasmids, (iii) as a separate Cas13 protein and a guide polynucleotide, or (iv) as an RNP complex of a Cas13 protein and a guide polynucleotide.

[0236] In some embodiments, the CRISPR-Cas13 system, composition or kit comprises a nucleic acid molecule encoding the Cas13 protein, wherein the coding sequence is codon optimized for expression in eukaryotic cells. In some embodiments, the CRISPR-Cas13 system, composition or kit comprises a nucleic acid molecule encoding the Cas13 protein, wherein the coding sequence is codon optimized for expression in mammalian cells. In some embodiments, the CRISPR-Cas13 system, composition or kit comprises a nucleic acid molecule encoding the Cas13 protein, wherein the coding sequence is codon optimized for expression in human cells.

[0237] In some embodiments, the nucleic acid molecule encoding the Cas13 protein is a plasmid. In some embodiments, the nucleic acid molecule encoding the Cas13 protein is part of a viral vector genome, such as a DNA genome of an AAV vector flanked by ITRs. In some embodiments, the nucleic acid molecule encoding the Cas13 protein is mRNA.

[0238] Guide polynucleotide

[0239] In some embodiments, the guidance polynucleotide of the CRISPR-Cas13 system is a guide RNA. In some embodiments, the guidance polynucleotide is a chemically modified guidance polynucleotide. In some embodiments, the guidance polynucleotide comprises at least one chemically modified nucleotide. In some embodiments, the guidance polynucleotide is a hybrid RNA-DNA guidance. In some embodiments, the guidance polynucleotide is a hybrid RNA-LNA (locked nucleic acid) guidance.

[0240] In some embodiments, the guide polynucleotide comprises at least one guide sequence (also known as a spacer sequence) linked to at least one direct repeat (DR). In some embodiments, the guide sequence is located at the 3' end of the direct repeat. In some embodiments, the guide sequence is located at the 5' end of the direct repeat.

[0241] In some embodiments, the guide sequence comprises at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, or at least 30 nucleotides. In some embodiments, the guide sequence comprises no more than 60 nucleotides, no more than 55 nucleotides, no more than 50 nucleotides, no more than 45 nucleotides, no more than 40 nucleotides, no more than 35 nucleotides, or no more than 30 nucleotides. In some embodiments, the guide sequence comprises 15-20 nucleotides, 20-25 nucleotides, 25-30 nucleotides, 30-35 nucleotides, or 35-40 nucleotides.

[0242] In some embodiments, the guide sequence has sufficient complementarity to the target RNA sequence to hybridize with the target RNA and guide sequence-specific binding of the CRISPR-Cas13 complex to the target RNA. In some embodiments, the guide sequence has 100% complementarity to the target RNA (or region of the RNA to be targeted), but the guide sequence can have less than 100% complementarity to the target RNA, such as at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% complementarity.

[0243] In some embodiments, the guide sequence is engineered to hybridize to the target RNA with no more than two nucleotide mismatches. In some embodiments, the guide sequence is engineered to hybridize to the target RNA with no more than one nucleotide mismatches. In some embodiments, the guide sequence is engineered to hybridize to the target RNA with or without mismatches.

[0244] In some embodiments, the same direction repeat sequence comprises at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides or at least 36 nucleotides. In some embodiments, the same direction repeat sequence comprises no more than 60 nucleotides, no more than 55 nucleotides, no more than 50 nucleotides, no more than 45 nucleotides, no more than 40 nucleotides or no more than 35 nucleotides. In some embodiments, the same direction repeat sequence comprises 20-25 nucleotides, 25-30 nucleotides, 30-35 nucleotides or 35-40 nucleotides.

[0245] In some embodiments, the repeat sequence in the same direction is modified to replace at least one complementary base pair in the stem region shown in Figure 2 with different complementary base pairs. In some embodiments, the repeat sequence in the same direction is modified to change the number of complementary base pairs in the stem region shown in Figure 2. In some embodiments, the repeat sequence in the same direction is modified to change the number of nucleotides in the loop region shown in Figure 2 (for example, 3, 4 or 5 nucleotides in the loop). In some embodiments, the repeat sequence in the same direction is modified to change the nucleotide sequence in the loop region. In some embodiments, an aptamer sequence is inserted into or attached to the end of the repeat sequence in the same direction. In some embodiments, the direct repeat sequence has at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity compared to any one of SEQ ID NO:3 and SEQ ID NOs:80-87.

[0246] In some embodiments, the CRISPR-Cas13 system, composition, or kit comprises at least 2, at least 3, at least 4, at least 5, at least 10, or at least 20 different guide polynucleotides. In some embodiments, the guide polynucleotides target at least 2, at least 3, at least 4, at least 5, at least 10, or at least 20 different target RNA molecules, or target at least 2, at least 3, at least 4, at least 5, at least 10, or at least 20 different regions of one or more target RNA molecules.

[0247] In some embodiments, the guidance polynucleotide includes a constant directional repeat sequence located upstream of the variable guide sequence. In some embodiments, a plurality of guidance polynucleotides are a part for an array (which can be a part for a vector, such as a viral vector or a plasmid). For example, the guidance array including the sequence DR-spacer-DR-spacer-DR-spacer can include three unique unprocessed guidance polynucleotides (one for each DR-spacer sequence). Once introduced into a cell or a cell-free system, the array is processed into three separate mature guidance polynucleotides by the Cas13 protein. This allows multiplexing, such as by delivering a plurality of guidance polynucleotides to a cell or system to target multiple target RNAs or multiple regions within a single target RNA.

[0248] The ability of a guide polynucleotide to direct sequence-specific binding of a CRISPR complex to a target RNA can be assessed by any suitable assay. For example, components of a CRISPR system sufficient to form a CRISPR complex, including the guide polynucleotide to be tested, can be provided to a host cell with a corresponding target RNA molecule, such as by transfection of a vector encoding the components of the CRISPR complex, and preferential cleavage within the target sequence can be assessed. Similarly, cleavage of a target RNA sequence can be assessed in a test tube by providing the target RNA, components of a CRISPR complex, including the guide polynucleotide to be tested and a control guide polynucleotide that is different from the test guide polynucleotide, and comparing the ability to bind to the target RNA or the rate at which the target RNA is cleaved between the test and control guide polynucleotides.

[0249] Cas13 mutants

[0250] In some embodiments, the Cas13 proteins provided herein comprise one or more mutations, such as single amino acid insertions, single amino acid deletions, single amino acid substitutions, or a combination thereof, compared to wild-type C13-2 protein (SEQ ID NO: 1). In some instances, the Cas13 proteins comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 , 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89 or 90 amino acid changes (e.g., insertions, deletions or substitutions) but retain the ability to bind to a target RNA molecule that is complementary to the guide sequence of the guide polynucleotide and / or retain the ability to process guide array RNA transcripts into guide polynucleotide molecules. In some examples, the wild-type C13-2 protein (SEQ ID NO: 1) comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 2, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89 or 90 amino acid changes (e.g., insertions, deletions or substitutions) but retains the ability to bind to a target RNA molecule that is complementary to the guide sequence of the guide polynucleotide.In some examples, the Cas13 protein comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acid changes (e.g., insertions, deletions, or substitutions) compared to the wild-type C13-2 protein (SEQ ID NO: 1), but retains the ability to bind to a target RNA molecule that is complementary to the guide sequence of the guide polynucleotide, and / or retains the ability to process guide array RNA transcripts into guide polynucleotide molecules.

[0251] In some embodiments, the Cas13 protein comprises one or more mutations in the catalytic domain and has reduced RNA cleavage activity. In some embodiments, the Cas13 protein comprises a mutation in the catalytic domain and has reduced RNA cleavage activity. In some embodiments, the Cas13 protein comprises one or more mutations in one or two HEPN domains and substantially lacks RNA cleavage activity. In some embodiments, the Cas13 protein comprises a mutation in one or two HEPN domains and substantially lacks RNA cleavage activity. In some embodiments, the “substantially lacking RNA cleavage activity” refers to retaining only ≤50%, ≤40%, ≤30%, ≤20%, ≤10%, ≤5% or ≤1% RNA cleavage activity compared to the wild-type Cas13 protein, or no detectable RNA cleavage activity.

[0252] In some embodiments, the Cas13 protein has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity compared to SEQ ID NO: 1. In some embodiments, the Cas13 protein has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity compared to the protein sequence encoded by SEQ ID NO: 9. When the CRISPR-Cas13 system comprises a fusion protein of the Cas13 with a protein domain and / or a polypeptide tag, the percentage of sequence identity between the Cas13 portion of the fusion protein and the reference sequence is calculated.

[0253] In some embodiments, the Cas13 protein can form a CRISPR complex with a guide polynucleotide, and the CRISPR complex can specifically bind to a target RNA sequence.

[0254] In some embodiments, the Cas13 protein is capable of forming a CRISPR complex with a guide polynucleotide comprising a direct repeat sequence linked to a guide sequence engineered to direct sequence-specific binding of the CRISPR complex to a target RNA.

[0255] A type of modification or mutation includes replacing an amino acid residue with a similar biochemical property with an amino acid, i.e., a conservative substitution (e.g., a conservative substitution of 1-4, 1-8, 1-10, or 1-20 amino acids). Typically, conservative substitutions have little or no effect on the activity of the resulting protein or peptide. For example, conservative substitutions are amino acid substitutions in Cas13 proteins that substantially do not affect the binding of Cas13 proteins to target RNA molecules complementary to the gRNA molecule guide sequence, and / or the process of processing guide array RNA transcripts into gRNA molecules. Alanine scanning can be used to identify which amino acid residues in Cas13 proteins can tolerate amino acid substitutions. In one example, when alanine or other conservative amino acids are replaced by 1-4, 1-8, 1-10, or 1-20 natural amino acids, the change in the ability of variant Cas13 proteins to modify gene expression in the CRISPR-Cas system is no more than 25%, for example, no more than 20%, for example, no more than 10%. Examples of amino acids that can be substituted and are considered conservative substitutions include: Ala for Ser; Arg for Lys; Asn for Gln or His; Asp for Glu; Cys for Ser; Gln for Asn; Glu for Pro for Gly; His for Asn or Gln; Ile for Leu or Val; Leu for Ile or Val; Lys for Arg or Gln; Met for Leu or Ile; Phe for Met, Leu or Tyr; Ser for Thr; Ser for Thr; Trp for Tyr; Tyr for Trp or Phe; Val for Ile or Leu.

[0256] More substantial changes can be made by using less conservative substitutions, for example, by selecting residues that differ more in maintaining: (a) the structure of the polypeptide backbone in the region where the substitution occurs, for example, as a helical or sheet conformation; (b) the charge or hydrophobicity of the region that interacts with the target site; or (c) the bulk of the side chain. Substitutions that would generally be expected to produce the greatest changes in polypeptide function are (a) substitutions between a hydrophilic residue (e.g., serine or threonine) and a hydrophobic residue (e.g., leucine, isoleucine, phenylalanine, valine, or alanine); (b) substitutions between cysteine ​​or proline and any other residue; (c) substitutions between a residue with a positively charged side chain (e.g., lysine, arginine, or histidine) and a negatively charged residue (e.g., glutamic acid or aspartic acid); or (d) substitutions between a residue with a bulky side chain (e.g., phenylalanine) and a residue without a side chain (e.g., glycine).

[0257] In some embodiments, the Cas13 protein comprises one or more mutations at amino acid positions 40-91 of SEQ ID NO:1 (i.e., the region from the 40th amino acid to the 91st amino acid in the SEQ ID NO:1 sequence, including the 40th amino acid and the 91st amino acid). In some embodiments, the Cas13 protein comprises one or more mutations at amino acid positions 146-153 of SEQ ID NO:1. In some embodiments, the Cas13 protein comprises one or more mutations at amino acid positions 158-176 of SEQ ID NO:1. In some embodiments, the Cas13 protein comprises one or more mutations at amino acid positions 182-209 of SEQ ID NO:1. In some embodiments, the Cas13 protein comprises one or more mutations at amino acid positions 216-253 of SEQ ID NO:1. In some embodiments, the Cas13 protein comprises one or more mutations at amino acid positions 271-287 of SEQ ID NO:1. In some embodiments, the Cas13 protein comprises one or more mutations at amino acid positions 341-353 of SEQ ID NO:1. In some embodiments, the Cas13 protein comprises one or more mutations at amino acid positions 379-424 of SEQ ID NO: 1. In some embodiments, the Cas13 protein comprises one or more mutations at amino acid positions 456-477 of SEQ ID NO: 1. In some embodiments, the Cas13 protein comprises one or more mutations at amino acid positions 521-557 of SEQ ID NO: 1. In some embodiments, the Cas13 protein comprises one or more mutations at amino acid positions 575-588 of SEQ ID NO: 1. In some embodiments, the Cas13 protein comprises one or more mutations at amino acid positions 609-625 of SEQ ID NO: 1. In some embodiments, the Cas13 protein comprises one or more mutations at amino acid positions 700-721 of SEQ ID NO: 1. In some embodiments, the Cas13 protein comprises one or more mutations at amino acid positions 724-783 of SEQ ID NO: 1. In some embodiments, the Cas13 protein comprises one or more mutations at amino acid positions 796-815 of SEQ ID NO: 1. In some embodiments, the Cas13 protein comprises one or more mutations at amino acid positions 828-852 of SEQ ID NO: 1. In some embodiments, the Cas13 protein comprises one or more mutations at amino acid positions 880-893 of SEQ ID NO: 1.

[0258] In some embodiments, the Cas13 protein comprises a deletion of one or more amino acids at amino acid positions 348-350 of SEQ ID NO: 1 (i.e., the 348th, 349th, and 350th amino acids in the SEQ ID NO: 1 sequence). In some embodiments, the Cas13 protein comprises a deletion of one or more amino acids at amino acid positions 521-556 of SEQ ID NO: 1. In some embodiments, the Cas13 protein comprises a deletion of one or more amino acids at amino acid positions 883-893 of SEQ ID NO: 1.

[0259] In some embodiments, the RxxxxH motif (x represents any amino acid, RxxxxH can also be written as Rx4H or R4xH) of the Cas13 protein comprises one or more mutations and substantially lacks RNA cleavage activity.

[0260] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to the RxxxxH motif at positions 210-215, the RxxxxH motif at positions 750-755, and / or the RxxxxH motif at positions 785-790 of the reference protein shown in SEQ ID NO: 1.

[0261] In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to the RxxxxH motif at positions 210-215 of the reference protein set forth in SEQ ID NO: 1. In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to the RxxxxH motif at positions 750-755 of the reference protein set forth in SEQ ID NO: 1. In some embodiments, the Cas13 protein comprises a mutation at a position corresponding to the RxxxxH motif at positions 785-790 of the reference protein set forth in SEQ ID NO: 1.

[0262] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to the RxxxxH motif at positions 210-215 and the RxxxxH motif at positions 750-755 of the reference protein shown in SEQ ID NO: 1.

[0263] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to the RxxxxH motif at positions 210-215 and the RxxxxH motif at positions 785-790 of the reference protein shown in SEQ ID NO: 1.

[0264] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to the RxxxxH motif at positions 750-755 and the RxxxxH motif at positions 785-790 of the reference protein shown in SEQ ID NO: 1.

[0265] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to the RxxxxH motif at positions 210-215, the RxxxxH motif at positions 750-755, and the RxxxxH motif at positions 785-790 of the reference protein shown in SEQ ID NO: 1.

[0266] In some embodiments, the RxxxxH motif is mutated to AxxxxH, RxxxxA, or AxxxxA. In some embodiments, the RxxxxH motif is mutated to AxxxxH. In some embodiments, the RxxxxH motif is mutated to RxxxxA. In some embodiments, the RxxxxH motif is mutated to AxxxxA.

[0267] In some embodiments, the Cas13 protein comprises 1, 2, 3, 4, 5, or 6 mutations at positions corresponding to amino acid residues R210, H215, R750, H755, R785, and / or H790 of the reference protein set forth in SEQ ID NO: 1. In some embodiments, the Cas13 protein is mutated to A (alanine) at positions corresponding to amino acid residues R210, H215, R750, H755, R785, and / or H790 of the reference protein set forth in SEQ ID NO: 1.

[0268] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R210 and H215 of the reference protein set forth in SEQ ID NO: 1. In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R750 and H755 of the reference protein set forth in SEQ ID NO: 1. In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R785 and H790 of the reference protein set forth in SEQ ID NO: 1.

[0269] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R210, H215, R750, and H755 of the reference protein set forth in SEQ ID NO: 1.

[0270] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R750, H755, R785, and H790 of the reference protein set forth in SEQ ID NO: 1.

[0271] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R210, H215, R785 and / or H790 of the reference protein set forth in SEQ ID NO: 1.

[0272] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R210, H215, R750, H755, R785, and H790 of the reference protein set forth in SEQ ID NO: 1.

[0273] In some embodiments, the corresponding positions of R210, R750, or R785 are mutated to A. In some embodiments, the corresponding positions of H215, H755, or H790 are mutated to A. In some embodiments, the corresponding positions of R210, H215, R750, H755, R785, and H790 are all mutated to A.

[0274] In some embodiments, the Cas13 protein is obtained by introducing mutations into the RxxxxH motif at positions 210-215, the RxxxxH motif at positions 750-755, and / or the RxxxxH motif at positions 785-790 of the sequence shown in SEQ ID NO: 1.

[0275] In some embodiments, the Cas13 protein is obtained by introducing 1, 2, 3, 4, 5 or 6 mutations at positions R210, H215, R750, H755, R785 and / or H790 of the sequence shown in SEQ ID NO: 1. In some embodiments, the Cas13 protein is obtained by mutating positions R210, H215, R750, H755, R785 and / or H790 of the sequence shown in SEQ ID NO: 1 to A (alanine).

[0276] In some embodiments, the Cas13 protein is obtained by mutating R210, H215, R785, and H790 of the sequence shown in SEQ ID NO: 1 to A. In some embodiments, the Cas13 protein is obtained by mutating R210, H215, R750, and H755 of the sequence shown in SEQ ID NO: 1 to A. In some embodiments, the Cas13 protein is obtained by mutating R750, H755, R785, and H790 of the sequence shown in SEQ ID NO: 1 to A. In some embodiments, the Cas13 protein is obtained by mutating R210, H215, R750, H755, R785, and H790 of the sequence shown in SEQ ID NO: 1 to A.

[0277] In some embodiments, the Cas13 protein comprises at least one mutation at positions corresponding to amino acid residues 40-91, 146-153, 158-176, 182-209, 216-253, 271-287, 341-353, 379-424, 456-477, 521-557, 575-588, 609-625, 700-721, 724-783, 796-815, 828-852, or 880-893 of the reference protein set forth in SEQ ID NO: 1. In some embodiments, the Cas13 protein comprises a deletion of one or more amino acids at positions corresponding to amino acid residues 348-350, 521-556, or 883-893 of the reference protein set forth in SEQ ID NO: 1.

[0278] In some embodiments, the Cas13 protein comprises any one or more mutations at positions corresponding to the following amino acid residues of the reference protein as compared to SEQ ID NO: 1: R11, N34, R35, R47, R58, R63, R64, N68, N87, N265, N274, R276, R290, R294, N299, N303, R308, R314, R320, R328, N332, R341, N346, R358, N372, N383, N390, N394, R47+R290, R47+R314, R290+R314, R47+R290+R314, R308+N6 8. N394+N68, N87+N68, R308+N265, N394+N265, N87+N265, R308+N68+N265, N87+N68+N265, T7, A16, S260, A263, M266, N274, F288, M 302, N303, L304, V305, I311, D313, H324, P326, H327, N332, N346, T353, T360, E365, A373, M380, S382, K395, Y396, D402, D411, S418.

[0279] In some embodiments, compared to the reference protein shown in SEQ ID NO: 1, the Cas13 protein is mutated to the same amino acid residue at the corresponding position of the mutation site of the reference protein shown in SEQ ID NO: 1 in Table 24. In some embodiments, compared to the reference protein shown in SEQ ID NO: 1, the Cas13 protein comprises the same mutation at the corresponding position of the mutation site of the reference protein shown in SEQ ID NO: 1 in Table 24.

[0280] In some embodiments, the Cas13 protein is obtained by introducing any one or more mutations into the following positions of the sequence shown in SEQ ID NO: 1: R11, N34, R35, R47, R58, R63, R64, N68, N87, N265, N274, R276, R290, R294, N299, N303, R308, R314, R320, R328, N332, R341, N346, R358, N372, N383, N390, N394, R47+R290, R47+R314, R290+R314, R47+R290+R314, R308+N68, N3 94+N68, N87+N68, R308+N265, N394+N265, N87+N265, R308+N68+N265, N87+N68+N265, T7, A16, S260, A263, M266, N274, F288, M30 2. N303, L304, V305, I311, D313, H324, P326, H327, N332, N346, T353, T360, E365, A373, M380, S382, K395, Y396, D402, D411, S418.

[0281] In some embodiments, the Cas13 protein is obtained by introducing any one or more mutations in Table 24 into the sequence shown in SEQ ID NO: 1.

[0282] In some embodiments, the Cas13 protein is obtained by deleting the sequence at the corresponding positions of amino acid residues 91-120, 141-180, 211-240, 331-360, 351-400, 431-460, 461-500, 511-550, 611-640, 631-660, 661-690, 691-760, 821-860, or 861-890 of the reference protein shown in SEQ ID NO: 1.

[0283] In some embodiments, the sequence deletion is deleted from ≤300, ≤200, ≤150, ≤100, ≤90, ≤80, ≤70, ≤60, ≤50, ≤40, ≤30, ≤20, or ≤10 amino acid residues.

[0284] In some embodiments, the Cas13 protein is obtained by deleting the sequence of SEQ ID NO: 1 at positions 91-120, 141-180, 211-240, 331-360, 351-400, 431-460, 461-500, 511-550, 611-640, 631-660, 661-690, 691-760, 821-860, or 861-890.

[0285] Subcellular localization signal (or localization signal)

[0286] In some embodiments, the Cas13 protein or its functional fragment is fused to at least one homologous or heterologous subcellular localization signal. Exemplary subcellular localization signals include organelle localization signals, such as nuclear localization signals (NLS), nuclear export signals (NES) or mitochondrial localization signals.

[0287] In some embodiments, the Cas13 protein or its functional fragment is fused to at least one homologous or heterologous NLS. In some embodiments, the Cas13 protein or its functional fragment is fused to at least two NLSs. In some embodiments, the Cas13 protein or its functional fragment is fused to at least three NLSs. In some embodiments, the Cas13 protein or its functional fragment is fused to at least one N-terminal NLS and at least one C-terminal NLS. In some embodiments, the Cas13 protein or its functional fragment is fused to at least two C-terminal NLSs. In some embodiments, the Cas13 protein or its functional fragment is fused to at least two N-terminal NLSs.

[0288] In some embodiments, the NLS is independently selected from SPKKKRKVEAS (SEQ ID NO: 53), GPKKKRKVAAA (SEQ ID NO: 54), PKKKRKV (SEQ ID NO: 55), KRPAATKKA GQA KKKK (SEQ ID NO: 56), PAAKRVKLD (SEQ ID NO: 57), RQRRNELKRSP (SEQ ID NO: 58), NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY (SEQ ID NO: 59), RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV (SEQ ID NO: 60), VSRKRPRP (SEQ ID NO: 61), PPKKARED (SEQ ID NO: 62), POPKKKPL (SEQ ID NO: 63), SALIKKKKKMAP (SEQ ID NO: 64), DRLRR (SEQ ID NO: 65), NO:65), PKQKKRK (SEQ ID NO:66), RKLKKKIKKL (SEQ ID NO:67), REKKKFLKRR (SEQ ID NO:68), KRKGDEVDGVDEVAKKKSKK (SEQ ID NO:69), RKCLQAGMNLEARKTKK (SEQ ID NO:70) and PAAKKKKLD (SEQ ID NO:71).

[0289] In some embodiments, the Cas13 protein or its functional fragment is fused to a homologous or heterologous NES. In some embodiments, the Cas13 protein or its functional fragment is fused to at least two NES. In some embodiments, the Cas13 protein or its functional fragment is fused to at least three NES. In some embodiments, the Cas13 protein or its functional fragment is fused to at least one N-terminal NES and at least one C-terminal NES. In some embodiments, the Cas13 protein or its functional fragment is fused to at least two C-terminal NES. In some embodiments, the Cas13 protein or its functional fragment is fused to at least two N-terminal NES.

[0290] In some embodiments, the NES is independently selected from the group consisting of an adenovirus type 5 E1B NES, an HIV Rev NES, a MAPK NES, and a PTK2 NES.

[0291] In some embodiments, the Cas13 protein or its functional fragment is fused to a homologous or heterologous NLS and NES, and there is a cleavable joint between the NLS and the NES. In some embodiments, the NES promotes the production of delivery particles (e.g., virus-like particles) comprising the Cas13 protein or its functional fragment in the production cell line. In some embodiments, the cutting of the joint in the target cell can expose the NLS and promote the nuclear localization of the Cas13 protein or its functional fragment in the target cell.

[0292] Protein domain and peptide tags

[0293] In some embodiments, the Cas13 protein or its functional fragment is covalently linked or fused to a homologous or heterologous protein domain and / or a polypeptide tag. In some embodiments, the Cas13 protein or its functional fragment is fused to a homologous or heterologous protein domain and / or a polypeptide tag.

[0294] In some embodiments, the protein domain and polypeptide tag are selected from: a cytosine deaminase domain, an adenosine deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter domain, an affinity domain, a subcellular localization signal, a reporter tag, and an affinity tag.

[0295] In some embodiments, the protein domain comprises a cytosine deaminase domain, an adenosine deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a ribonuclease domain, a splicing factor domain, a reporter domain, and an affinity domain. In some embodiments, the polypeptide tag comprises a reporter tag and an affinity tag.

[0296] In some embodiments, the length of the amino acid sequence of the protein domain is ≥40 amino acids, ≥50 amino acids, ≥60 amino acids, ≥70 amino acids, ≥80 amino acids, ≥90 amino acids, ≥100 amino acids, ≥150 amino acids, ≥200 amino acids, ≥250 amino acids, ≥300 amino acids, ≥350 amino acids, or ≥400 amino acids.

[0297] Exemplary protein domains include domains that can cleave RNA (e.g., PIN endonuclease domains, NYN domains, SMR domains from SOT1, or RNase domains from staphylococcal nuclease), domains that can affect RNA stability (e.g., tristetraprolin (TTP) or domains from UPF1, EXOSC5, and STAU1), domains that can edit nucleotides or ribonucleotides (e.g., cytidine deaminases, PPR proteins, adenosine deaminases, ADAR family proteins, or APOBEC family proteins), domains that can activate translation (e.g., domains of eIF4E and other translation initiation factors, yeast poly(A) binding protein, or GLD2), domains that can inhibit translation (e.g., Pumilio or FBF). These proteins may be cleaved from the mitochondrial fold change (PUF), deadenylase, CAF1, Argonaute proteins), domains that can methylate RNA (e.g., domains from m6A methyltransferase factors such as METTL14, METTL3, or WTAP), domains that can demethylate RNA (e.g., human alkylation repair homolog 5), domains that can affect splicing (e.g., the RS-rich domain of SRSF1, the Gly-rich domain of hnRNP A1, the alanine-rich motif of RBM4, or the proline-rich motif of DAZAP1), domains that can enable affinity purification or immunoprecipitation, and domains that can enable proximity-dependent protein tagging and recognition (e.g., biotin ligases such as BirA or peroxidases such as APEX2 to biotinylate target DNA-interacting proteins).

[0298] In some embodiments, the protein domain comprises an adenosine deaminase domain. In some embodiments, the Cas13 protein with a mutant HEPN domain, the catalytically inactive Cas13 protein, or its functional fragment is covalently linked or fused to the adenosine deaminase domain to guide the A-to-I deaminase activity of RNA transcripts in mammalian cells. Cox et al., Science 358 (6366): 1019-1027 (2017) describes an adenosine deaminase domain for targeting A-to-I RNA editing based on ADAR2 engineering, which is incorporated herein by reference in its entirety. In other embodiments, the adenosine deaminase domain is covalently linked or fused to a linker protein that is capable of binding to an aptamer sequence inserted into or attached to the guidance polynucleotide, thereby allowing the adenosine deaminase domain to be non-covalently linked to the Cas13 protein or its functional fragment compounded with the guidance polynucleotide.

[0299] In some embodiments, the protein domain includes a cytosine deaminase domain. In some embodiments, the Cas13 protein with a mutant HEPN domain, the catalytically inactivated Cas13 protein, or its functional fragment is covalently linked to or fused with a cytosine deaminase domain to guide the C-to-U deaminase activity of RNA transcripts in mammalian cells. Abudayyeh et al., Science 365 (6451): 382-386 (2019) describes a cytosine deaminase domain for targeting C-to-U RNA editing evolved from ADAR2, which is incorporated herein by reference in its entirety. In other embodiments, the cytosine deaminase domain is covalently linked to or fused with a linker protein that can bind to an aptamer sequence inserted into or attached to the guidance polynucleotide, thereby allowing the cytosine deaminase domain to be non-covalently linked to the Cas13 protein or its functional fragment compounded with the guidance polynucleotide.

[0300] In some embodiments, the protein domain comprises a splicing factor domain. In some embodiments, the Cas13 protein with a mutant HEPN domain, the catalytically inactivated Cas13 protein, or its functional fragment is covalently linked or fused to a splicing factor domain to guide the alternative splicing of target RNA in mammalian cells. Konermann et al., Cell 173 (3): 665-676 (2018) describes a splicing factor domain for targeted alternative splicing, which is incorporated herein by reference in its entirety. Non-limiting examples of splicing factor domains include the RS-rich domain of SRSF1, the Gly-rich domain of hnRNPA1, the alanine-rich motif of RBM4, or the proline-rich motif of DAZAP1. In other embodiments, the splicing factor domain is covalently linked or fused to a linker protein that is capable of binding to an aptamer sequence inserted into or attached to the guidance polynucleotide, thereby allowing the splicing factor domain to be non-covalently linked to the Cas13 protein or its functional fragment compounded with the guidance polynucleotide.

[0301] In some embodiments, the protein domain includes a translation activation domain. In some embodiments, the Cas13 protein with a mutation HEPN domain, the catalytically inactive Cas13 protein or its functional fragment is covalently linked to or fused with a translation activation domain to activate or increase the expression of the target RNA. Non-limiting examples of translation activation domains include eIF4E and other translation initiation factors, yeast poly (A) binding protein or the domain of GLD2. In other embodiments, the translation activation domain is covalently linked or fused to a linker protein that can bind to an aptamer sequence inserted into or attached to the guidance polynucleotide, thereby allowing the translation activation domain to be non-covalently linked to the Cas13 protein or its functional fragment compounded with the guidance polynucleotide.

[0302] In some embodiments, the protein domain comprises a translation inhibition domain. In some embodiments, the Cas13 protein with a mutant HEPN domain, the catalytically inactive Cas13 protein, or a functional fragment thereof is covalently linked or fused to a translation inhibition domain to inhibit or reduce the expression of the target RNA. Non-limiting examples of translation inhibition domains include Pumilio or FBF PUF proteins, deadenylases, CAF1, Argonaute proteins. In other embodiments, the translation inhibition domain is covalently linked or fused to a linker protein that is capable of binding to an aptamer sequence inserted into or attached to the guide polynucleotide, thereby allowing the translation inhibition domain to be non-covalently linked to the Cas13 protein or its functional fragment complexed with the guide polynucleotide.

[0303] In some embodiments, the protein domain comprises an RNA methylation domain. In some embodiments, the Cas13 protein having a mutant HEPN domain, the catalytically inactive Cas13 protein, or a functional fragment thereof is covalently linked or fused to an RNA methylation domain for methylation of the target RNA. Non-limiting examples of RNA methylation domains include m6A domains, such as METTL14, METTL3, or WTAP. In other embodiments, the RNA methylation domain is covalently linked or fused to an adapter protein that is capable of binding to an aptamer sequence inserted into or attached to the guide polynucleotide, thereby allowing the RNA methylation domain to be non-covalently linked to the Cas13 protein or its functional fragment complexed with the guide polynucleotide.

[0304] In some embodiments, the protein domain comprises an RNA demethylation domain. In some embodiments, the Cas13 protein having a mutant HEPN domain, the catalytically inactive Cas13 protein, or a functional fragment thereof is covalently linked or fused to an RNA demethylation domain for demethylation of the target RNA. Non-limiting examples of RNA demethylation domains include human alkylation repair homolog 5 or ALKBH5. In other embodiments, the RNA demethylation domain is covalently linked or fused to an adapter protein that is capable of binding to an aptamer sequence inserted into or attached to the guide polynucleotide, thereby allowing the RNA demethylation domain to be non-covalently linked to the Cas13 protein or its functional fragment complexed with the guide polynucleotide.

[0305] In some embodiments, the protein domain comprises a ribonuclease domain. In some embodiments, the Cas13 protein having a mutant HEPN domain, the catalytically inactive Cas13 protein, or a functional fragment thereof is covalently linked or fused to a ribonuclease domain to cleave the target RNA. Non-limiting examples of ribonuclease domains include a PIN endonuclease domain, a NYN domain, an SMR domain from SOT1, or an RNase domain from staphylococcal nuclease.

[0306] In some embodiments, the protein domain comprises an affinity domain (affinity domain) and / or a reporter domain (reporter domain). In some embodiments, the Cas13 protein or its functional fragment is covalently linked or fused to a reporter domain, such as a fluorescent protein. Non-limiting examples of reporter domains include GST, HRP, CAT, GFP, HcRed, DsRed, CFP, YFP, BFP.

[0307] In some embodiments, the Cas13 protein is covalently linked to or fused with a polypeptide tag. In some embodiments, the example of the polypeptide tag is a small polypeptide sequence. In some embodiments, the length of the amino acid sequence of the polypeptide tag is ≤50 amino acids, ≤40 amino acids, ≤30 amino acids, ≤25 amino acids, ≤20 amino acids, ≤15 amino acids, ≤10 amino acids or ≤5 amino acids. In some embodiments, the Cas13 protein is covalently linked to or fused with an affinity tag such as a purification tag. Non-limiting examples of affinity tags include HA-tags, His-tags (e.g., 6-His), Myc-tags, E-tags, S-tags, calmodulin tags, FLAG-tags, GST-tags, MBP-tags, Halo tags or biotin.

[0308] In some embodiments, the C13-2 inactivation mutant (R210A+H215A+R750A+H755A+R785A+H790A) is fused to a protein domain and / or polypeptide tag.

[0309] In some embodiments, the Cas13 protein is fused to an ADAR.

[0310] In some embodiments, the C13-2 inactivation mutant (R210A+H215A+R750A+H755A+R785A+H790A) is fused to cytosine deaminase or adenine deaminase.

[0311] In some embodiments, the C13-2 inactive mutant (R210A+H215A+R750A+H755A+R785A+H790A) is covalently linked to cytosine deaminase or adenine deaminase directly, through a rigid linker peptide sequence A (EAAAK) 3A, or through a flexible linker peptide sequence (GGGGS) 3.

[0312] Aptamer Sequence

[0313] In some embodiments, the guide polynucleotide further comprises an aptamer sequence. In some embodiments, the aptamer sequence is inserted into a loop of the guide polynucleotide. In some embodiments, the aptamer sequence is inserted into a tetra loop of the guide polynucleotide. An exemplary tetra loop of a guide polynucleotide is shown in Figure 2. In some embodiments, the aptamer sequence is attached to the end of the guide polynucleotide.

[0314] Inserting an aptamer sequence into a guide polynucleotide of a CRISPR-Cas system is described in Konermann et al., Nature 517:583–588 (2015), which is incorporated herein by reference in its entirety. In some embodiments, the aptamer sequence comprises an MS2 aptamer sequence, a PP7 aptamer sequence, or a Qβ aptamer sequence.

[0315] Adaptor protein

[0316] In some embodiments, the CRISPR-Cas13 system further comprises a fusion protein comprising an adaptor protein and a homologous or heterologous protein domain and / or polypeptide tag, or a nucleic acid encoding the fusion protein, wherein the adaptor protein is capable of binding to an aptamer sequence.

[0317] Konermann et al., Nature 517:583-588 (2015) describes a fusion protein of a connector protein and a protein domain, which is incorporated herein by reference in its entirety. In some embodiments, the connector protein includes an MS2 phage coat protein (MCP), a PP7 phage coat protein (PCP), or a Qβ phage coat protein (QCP). In some embodiments, the protein domain includes a cytosine deaminase domain, an adenosine deaminase domain, a translation activation domain, a translation inhibition domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, an affinity domain, or a reporter domain.

[0318] Modified guide polynucleotides

[0319] In some embodiments, the guidance polynucleotide comprises a modified nucleotide. In some embodiments, the modified nucleotide comprises a 2'-O-methyl, a 2'-O-methyl-3'-phosphorothioate, or a 2'-O-methyl-3'-thioPACE. In some embodiments, the guidance polynucleotide is a chemically modified guidance polynucleotide. Chemically modified guidance polynucleotides are described in Hendel et al., Nat. Biotechnol. 33(9): 985-989 (2015), which is incorporated herein by reference in its entirety.

[0320] In some embodiments, the guide polynucleotide is a hybrid RNA-DNA guide, a hybrid RNA-LNA (locked nucleic acid) guide, a hybrid DNA-LNA guide, or a hybrid DNA-RNA-LNA guide. In some embodiments, the direct repeat sequence comprises one or more ribonucleotides substituted with corresponding deoxyribonucleotides. In some embodiments, the guide sequence comprises one or more ribonucleotides substituted with corresponding deoxyribonucleotides. Hybrid RNA-DNA guide polynucleotides are described in WO2016 / 123230, which is incorporated herein by reference in its entirety.

[0321] Vector system

[0322] Another aspect of the present disclosure relates to a vector system comprising the CRISPR-Cas13 system described herein, comprising one or more vectors comprising a polynucleotide sequence encoding the Cas13 protein or fusion protein and a polynucleotide sequence encoding the guide polynucleotide.

[0323] In some embodiments, the vector system comprises at least one plasmid or viral vector (e.g., retrovirus, lentivirus, adenovirus, adeno-associated virus, or herpes simplex virus). In some embodiments, the polynucleotide sequence encoding the Cas13 protein or fusion protein and the polynucleotide sequence encoding the guide polynucleotide are located on the same vector. In some embodiments, the polynucleotide sequence encoding the Cas13 protein or fusion protein and the polynucleotide sequence encoding the guide polynucleotide are located on multiple vectors.

[0324] In some embodiments, the polynucleotide sequence of the coding Cas13 protein or fusion protein and / or the polynucleotide sequence of the coding guidance polynucleotide are operably connected to a regulatory sequence. In some embodiments, the polynucleotide sequence of the coding Cas13 protein or fusion protein is operably connected to a regulatory sequence. In some embodiments, the polynucleotide sequence of the coding guidance polynucleotide is operably connected to a regulatory sequence. In some embodiments, the regulatory sequence of the polynucleotide sequence of the coding Cas13 protein or fusion protein is identical or different from the regulatory sequence of the polynucleotide sequence of the coding guidance polynucleotide. In some embodiments, the regulatory sequence is optionally selected from promoters, enhancers, internal ribosome entry sites (IRES) and other expression control elements (for example, transcription termination signals, such as polyadenylation signals and poly-U sequences). In some embodiments, the regulatory sequence includes regulatory sequences that make nucleotide sequences constitutively expressed in many types of host cells, and regulatory sequences (for example, tissue-specific regulatory sequences) that make nucleotide sequences expressed only in certain host cells. Tissue-specific promoters can be directed to expression primarily in a desired tissue of interest, such as muscle, neurons, bone, skin, blood, specific organs (e.g., liver, pancreas), or specific cell types (e.g., lymphocytes). Regulatory sequences can also direct expression in a time-dependent manner, such as in a cell cycle-dependent or developmental stage-dependent manner, which may or may not be tissue- or cell type-specific. In some embodiments, the regulatory sequence is an enhancer element, such as the WPRE, CMV enhancer, the R-U5 segment in the LTR of HTLV-1, the SV40 enhancer, or the intron sequence between exons 2 and 3 of rabbit β-globin.

[0325] In some embodiments, the vector comprises a pol III promoter (e.g., U6 and H1 promoters), a pol II promoter (e.g., the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with an RSV enhancer), a cytomegalovirus (CMV) promoter (optionally with a CMV enhancer), an SV40 promoter, a dihydrofolate reductase promoter, a β-actin promoter, a phosphoglycerol kinase (PGK) promoter, or an EF1α promoter), or a pol III promoter and a pol II promoter.

[0326] In some embodiments, the promoter is a constitutive promoter, which is continuously active and not regulated by external signals or molecules. Suitable constitutive promoters include, but are not limited to, CMV, RSV, SV40, EF1α, CAG, and β-actin promoters. In some embodiments, the promoter is an inducible promoter regulated by external signals or molecules (e.g., transcription factors).

[0327] In some embodiments, the promoter is a tissue-specific promoter, which can be used to drive the tissue-specific expression of the Cas13 protein or fusion protein. Suitable muscle-specific promoters include but are not limited to CK8, MHCK7, myoglobin promoter (Mb), desmin (Desmin) promoter, muscle creatine kinase promoter (MCK) and variants thereof, and SPc5-12 synthetic promoters. Suitable immune cell-specific promoters include but are not limited to B29 promoter (B cells), CD14 promoter (monocytes), CD43 promoter (leukocytes and platelets), CD68 (macrophages) and SV40 / CD43 promoter (leukocytes and platelets). Suitable blood cell-specific promoters include but are not limited to CD43 promoter (leukocytes and platelets), CD45 promoter (hematopoietic cells), INF-β (hematopoietic cells), WASP promoter (hematopoietic cells), SV40 / CD43 promoter (leukocytes and platelets), and SV40 / CD45 promoter (hematopoietic cells). Suitable pancreas-specific promoters include, but are not limited to, elastase-1 promoter. Suitable endothelial cell-specific promoters include, but are not limited to, Fit-1 promoter and ICAM-2 promoter. Suitable neuronal tissue / cell-specific promoters include, but are not limited to, GFAP promoter (astroglial cells), SYN1 promoter (neurons), and NSE / RU5' (mature neurons). Suitable kidney-specific promoters include, but are not limited to, NphsI promoter (podocytes). Suitable bone-specific promoters include, but are not limited to, OG-2 promoter (osteoblasts, odontoblasts). Suitable lung-specific promoters include, but are not limited to, SP-B promoter (lung). Suitable liver-specific promoters include, but are not limited to, SV40 / Alb promoter. Suitable heart-specific promoters include, but are not limited to, α-MHC.

[0328] AAV vectors

[0329] Another aspect of the present disclosure relates to an adeno-associated viral (AAV) vector comprising the CRISPR-Cas13 system described herein, wherein the adeno-associated viral (AAV) vector comprises DNA encoding the Cas13 protein or fusion protein described herein and a guide polynucleotide.

[0330] Delivery of the CRISPR-Cas system by AAV vectors is described in Maeder et al., Nature Medicine 25:229-233 (2019), which is incorporated herein by reference in its entirety. In some embodiments, the AAV vector comprises an ssDNA genome comprising a Cas13 protein or fusion protein and a coding sequence for a guide polynucleotide flanked by ITRs.

[0331] In some embodiments, the CRISPR-Cas13 system described herein is packaged in an AAV vector, such as AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, and AAVrh74. In some embodiments, the CRISPR-Cas13 system described herein is packaged in an AAV vector comprising an engineered capsid with tissue tropism, such as an engineered muscle tropism capsid. Tabebordbar et al., Cell 184:4919-4938 (2021) describes engineering of AAV capsids with tissue tropism by directed evolution, which is incorporated herein by reference in its entirety.

[0332] lipid nanoparticles

[0333] Another aspect of the present disclosure relates to lipid nanoparticles (LNPs) comprising a CRISPR-Cas13 system described herein, wherein the LNP comprises a guide polynucleotide described herein, and an mRNA encoding a Cas13 protein or fusion protein described herein.

[0334] Gillmore et al., N.Engl.J.Med., 385:493-502 (2021) describes the LNP delivery of the CRISPR-Cas system, which is incorporated herein by reference in its entirety. In some embodiments, in addition to RNA payload (Cas13 mRNA and guide polynucleotides), lipid nanoparticles (LNPs) also include four components: cations or ionizable lipids, cholesterol, helper lipids, and PEG-lipids. In some embodiments, the cations or ionizable lipids include cKK-E12, C12-200, ALC-0315, DLin-MC3-DMA, DLin-KC2-DMA, FTT5, Moderna SM-102, and Intellia LP01. In some embodiments, the PEG-lipid includes PEG-2000-C-DMG, PEG-2000-DMG, or ALC-0159. In some embodiments, the helper lipid includes DSPC. The components of LNPs are described in Paunovska et al., Nature Reviews Genetics 23:265-280 (2022), which is incorporated herein by reference in its entirety.

[0335] Lentiviral vectors

[0336] Another aspect of the present disclosure relates to a lentiviral vector comprising a CRISPR-Cas13 system as described herein, wherein the lentiviral vector comprises a guide polynucleotide as described herein, and an mRNA encoding a Cas13 protein or fusion protein as described herein. In some embodiments, the lentiviral vector is pseudotyped with a homologous or heterologous envelope protein such as VSV-G. In some embodiments, the mRNA encoding the Cas13 protein or fusion protein is connected to an aptamer sequence.

[0337] RNP complex

[0338] Another aspect of the present disclosure relates to a ribonucleoprotein complex comprising a CRISPR-Cas13 system as described herein, wherein the ribonucleoprotein complex is formed by a guidance polynucleotide as described herein and a Cas13 protein or fusion protein. In some embodiments, the ribonucleoprotein complex can be delivered to eukaryotic cells, mammalian cells, or human cells by microinjection or electroporation. In some embodiments, the ribonucleoprotein complex can be packaged in virus-like particles and delivered to a mammal or human subject in vivo.

[0339] virus-like particles

[0340] Another aspect of the present disclosure relates to a virus-like particle (VLP) comprising the CRISPR-Cas13 system described herein, wherein the virus-like particle comprises: a guide polynucleotide as described herein, and a Cas13 protein or fusion protein; or a ribonucleoprotein complex consisting of the guide polynucleotide and the Cas13 protein or fusion protein.

[0341] Banskota et al. Cell 185(2):250-265(2022), Mangeot et al., Nature Communications 10(1):1-15(2019), Campbell, et al., Molecular Therapy 27:151-163(2019), Campbell, et al., Molecular Therapy, 27(2019):151-163 and Mangeot et al. Molecular Therapy, 19(9):1656-1666(2011) describe engineered VLPs, which are incorporated herein by reference in their entirety. In some embodiments, engineered virus-like particles (VLPs) are pseudotyped with homologous or heterologous envelope proteins, such as VSV-G. In some embodiments, the Cas13 protein is fused to a gag protein (e.g., MLVgag) via a cleavable linker, wherein the cleavage of the linker in the target cell exposes an NLS between the linker and the Cas13 protein. In some embodiments, the fusion protein comprises (e.g., from 5' to 3') a gag protein (e.g., MLVgag), one or more NES, a cleavable linker, one or more NLSs, and Cas13, as described in Banskota et al. Cell 185(2):250-265(2022). In some embodiments, the Cas13 protein is fused to a first dimerization domain, which is capable of dimerizing or heterodimerizing with a second dimerization domain fused to a membrane protein, wherein the presence of a ligand promotes the dimerization and enriches the Cas13 protein or fusion protein into VLPs, as described in Campbell, et al., Molecular Therapy 27:151-163(2019).

[0342] cell

[0343] Another aspect of the present disclosure relates to cells comprising CRISPR-Cas13 systems as described herein.Cells (for example, which can be used to produce cell-free systems) can be eukaryotic or prokaryotic.The examples of such cells include, but are not limited to, bacteria, archaebacteria, plants, fungi, yeast, insects, and mammalian cells, such as lactobacillus, lactococci, bacillus (for example, bacillus subtilis), Escherichia (for example, Escherichia coli), Clostridium, Saccharomyces or Pichia (such as saccharomyces cerevisiae or Pichia pastoris), Kluyveromyces lactis, Salmonella typhimurium, Drosophila cells, Caenorhabditis elegans cells, African clawed frog cells, SF9 cells, C129 cells, 293 cells, Neurospora and immortalized mammalian cell lines (for example, Hela cells, myeloid cell lines, and lymphoid cell lines).

[0344] In some embodiments, the cell is a prokaryotic cell, such as a bacterial cell, such as escherichia coli. In some embodiments, the cell is a eukaryotic cell, such as a mammalian cell or a human cell. In some embodiments, the cell is a primary eukaryotic cell, a stem cell, a tumor / cancer cell, a circulating tumor cell (CTC), a blood cell (for example, T cell, B cell, NK cell, Tregs etc.), a hematopoietic stem cell, a specialized immune cell (such as tumor infiltrating lymphocytes or tumor suppressor lymphocytes), a stromal cell (such as cancer associated fibroblasts etc.) in a tumor microenvironment. In some embodiments, the cell is the brain or neuronal cell (for example, neuron, astrocyte, microglia, retinal ganglion cell, rod / cone cell etc.) of a central or peripheral nervous system.

[0345] target RNA molecules

[0346] The CRISPR-Cas13 system, composition or kit described herein can be used to target one or more target RNA molecules, such as target RNA molecules present in biological samples, environmental samples (such as soil, air or water samples), etc. In some embodiments, the target RNA is a coding RNA, such as pre-mRNA or mature mRNA. In some embodiments, the target RNA is a nuclear RNA. In some embodiments, the target RNA is an RNA transcript located in a eukaryotic cell nucleus. In some embodiments, the target RNA is a non-coding RNA, such as a functional RNA, siRNA, microRNA, snRNA, snoRNA, piRNA, scaRNA, tRNA, rRNA, lncRNA or lincRNA.

[0347] In some embodiments, in addition to targeting target RNA molecules, the CRISPR-Cas13 systems, compositions or kits described herein perform one or more of the following functions on the target RNA: cutting one or more target RNA molecules or nicking one or more target RNA molecules, activating or upregulating one or more target RNA molecules, activating or inhibiting the translation of one or more target RNA molecules, inactivating one or more target RNA molecules, visualizing, labeling or detecting one or more target RNA molecules, binding one or more target RNA molecules, editing one or more target RNA molecules, transporting one or more target RNA molecules, and masking one or more target RNA molecules. In some instances, the CRISPR-Cas13 systems, compositions or kits described herein modify one or more target RNA molecules, and the modification of one or more target RNA molecules includes one or more of the following: RNA base substitution, RNA base deletion, RNA base insertion, breakage of target RNA, RNA methylation and RNA demethylation. In some embodiments, the CRISPR-Cas13 systems, compositions or kits described herein can target one or more target RNA molecules. In some embodiments, the CRISPR-Cas13 systems, compositions or kits described herein can bind to one or more target RNA molecules. In some embodiments, the CRISPR-Cas13 system, composition, or kit described herein can cut one or more target RNA molecules. In some embodiments, the CRISPR-Cas13 system, composition, or kit described herein can activate the translation of one or more target RNA molecules. In some embodiments, the CRISPR-Cas13 system, composition, or kit described herein can inhibit the translation of one or more target RNA molecules. In some embodiments, the CRISPR-Cas13 system, composition, or kit described herein can detect one or more target RNA molecules. In some embodiments, the CRISPR-Cas13 system, composition, or kit described herein can edit one or more target RNA molecules.

[0348] In some embodiments, the target RNA is AQp1 RNA. Knockdown of Aqp1 RNA levels using the CRISPR-Cas13 system described herein can reduce aqueous humor production and lower intraocular pressure, and can be used to treat diseases such as glaucoma. In some embodiments, the target RNA is AQp1 RNA, and the guide sequence of the guide polynucleotide is SEQ ID NO: 5.

[0349] In some embodiments, the target RNA is PTBP1 RNA. Knockdown of PTBP1 RNA levels using the CRISPR-Cas13 system described herein can promote the transdifferentiation of brain astrocytes into neurons, which can be used to treat diseases such as Parkinson's disease. In some embodiments, the target RNA is PTBP1 RNA, and the guide sequence of the guide polynucleotide is SEQ ID NO: 6.

[0350] In some embodiments, the target RNA is VEGFA RNA. Reducing the level of VEGFA RNA using the CRISPR-Cas13 system described herein can prevent choroidal neovascularization, which can be used to treat diseases such as age-related macular degeneration.

[0351] In some embodiments, the target RNA is ANGPTL3 RNA. Knockdown of ANGPTL3 RNA levels using the CRISPR-Cas13 system described herein can reduce blood lipids such as low-density lipoprotein cholesterol (LDL-C), and can be used to treat atherosclerotic cardiovascular diseases such as hyperlipidemia and familial hypercholesterolemia. In some embodiments, the target RNA is ANGPTL3 RNA, and the guide sequence of the guide polynucleotide is selected from any one or more of SEQ ID NOs: 42-49.

[0352] Therapeutic applications

[0353] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a CRISPR-Cas13 system as described herein, a Cas13 protein as described herein, a fusion protein as described herein, a guide polynucleotide as described herein, a nucleic acid as described herein, a vector system as described herein, a lipid nanoparticle as described herein, a lentiviral vector as described herein, a ribonucleoprotein complex as described herein, a virus-like particle as described herein, or a eukaryotic cell as described herein. The pharmaceutical composition may comprise, for example, an AAV vector encoding a Cas13 protein or fusion protein as described herein and a guide polynucleotide. The pharmaceutical composition may comprise, for example, a lipid nanoparticle comprising a guide polynucleotide as described herein and an mRNA encoding the Cas13 protein or fusion protein. The pharmaceutical composition may comprise, for example, a lentiviral vector comprising an mRNA encoding the Cas13 protein or fusion protein as described herein. The pharmaceutical composition may comprise, for example: a virus-like particle comprising a guide polynucleotide as described herein and a Cas13 protein or fusion protein; or a ribonucleoprotein complex formed by the guide polynucleotide and the Cas13 protein or fusion protein.

[0354] Another aspect of the present disclosure relates to the use of a CRISPR-Cas13 system described herein, a Cas13 protein described herein, a fusion protein described herein, a guide polynucleotide described herein, a nucleic acid described herein, a vector system described herein, a lipid nanoparticle described herein, a lentiviral vector described herein, a ribonucleoprotein complex described herein, a virus-like particle described herein, or a eukaryotic cell described herein to cut or edit a target RNA in a mammalian cell.

[0355] Another aspect of the present disclosure relates to the use of a CRISPR-Cas13 system described herein, a Cas13 protein described herein, a fusion protein described herein, a guide polynucleotide described herein, a nucleic acid described herein, a vector system described herein, a lipid nanoparticle described herein, a lentiviral vector described herein, a ribonucleoprotein complex described herein, a virus-like particle described herein, or a eukaryotic cell described herein for any of the following: cleaving or nicking one or more target RNA molecules, activating or upregulating one or more target RNA molecules, activating or inhibiting translation of one or more target RNA molecules, inactivating one or more target RNA molecules, visualizing, labeling or detecting one or more target RNA molecules, binding one or more target RNA molecules, transporting one or more target RNA molecules, and masking one or more target RNA molecules.

[0356] Another aspect of the present disclosure relates to the use of the CRISPR-Cas13 system described herein, the Cas13 protein described herein, the fusion protein described herein, the guide polynucleotide described herein, the nucleic acid described herein, the vector system described herein, the lipid nanoparticle described herein, the lentiviral vector described herein, the ribonucleoprotein complex described herein, the virus-like particle described herein, or the eukaryotic cell described herein to modify one or more target RNA molecules in mammalian cells, wherein the modification of the one or more target RNA molecules includes one or more of the following: RNA base substitution, RNA base deletion, RNA base insertion, fragmentation of the target RNA, RNA methylation and RNA demethylation.

[0357] Another aspect of the present disclosure relates to the use of the CRISPR-Cas13 system described herein, the Cas13 protein described herein, the fusion protein described herein, the guide polynucleotide described herein, the nucleic acid described herein, the vector system described herein, the lipid nanoparticle described herein, the lentiviral vector described herein, the ribonucleoprotein complex described herein, the virus-like particle described herein, or the eukaryotic cell described herein in the diagnosis, treatment, or prevention of a disease or condition associated with a target RNA. In some embodiments, the disease or condition is Parkinson's disease. In some embodiments, the disease or condition is Parkinson's disease and the target RNA is PTBP1 RNA. In some embodiments, the disease or condition is glaucoma. In some embodiments, the disease or condition is glaucoma and the target RNA is AQp1 RNA. In some embodiments, the disease or condition is amyotrophic lateral sclerosis. In some embodiments, the disease or condition is amyotrophic lateral sclerosis and the target RNA is superoxide dismutase 1 (SOD1) RNA. In some embodiments, the disease or condition is age-related macular degeneration and the target RNA is VEGFA RNA. In some embodiments, the disease or condition is age-related macular degeneration, and the target RNA is VEGFA RNA or VEGFR1 RNA. In some embodiments, the disease or condition is elevated plasma LDL cholesterol levels. In some embodiments, the disease or condition is elevated plasma LDL cholesterol levels, and the target RNA is PCSK9 RNA or ANGPTL3 RNA.

[0358] Another aspect of the present disclosure relates to the use of a CRISPR-Cas13 system as described herein, a Cas13 protein as described herein, a fusion protein as described herein, a guide polynucleotide as described herein, a nucleic acid as described herein, a vector system as described herein, a lipid nanoparticle as described herein, a lentiviral vector as described herein, a ribonucleoprotein complex as described herein, a virus-like particle as described herein, or a eukaryotic cell as described herein in the preparation of a medicament for diagnosing, treating, or preventing a disease or condition associated with a target RNA. In some embodiments, the disease or condition is Parkinson's disease. In some embodiments, the disease or condition is glaucoma. In some embodiments, the disease or condition is amyotrophic lateral sclerosis. In some embodiments, the disease or condition is age-related macular degeneration. In some embodiments, the disease or condition is elevated plasma LDL cholesterol levels. In some embodiments, the disease or condition is Parkinson's disease and the target RNA is PTBP1 RNA. In some embodiments, the disease or condition is glaucoma and the target RNA is AQp1 RNA. In some embodiments, the disease or condition is amyotrophic lateral sclerosis and the target RNA is superoxide dismutase 1 (SOD1) RNA. In some embodiments, the disease or condition is age-related macular degeneration and the target RNA is VEGFA RNA or VEGFR1 RNA. In some embodiments, the disease or condition is elevated plasma LDL cholesterol levels and the target RNA is PCSK9 RNA or ANGPTL3 RNA.

[0359] In some embodiments, the pharmaceutical composition is delivered to a human subject in vivo. The pharmaceutical composition can be delivered by any effective route. Exemplary routes of administration include, but are not limited to, intravenous infusion, intravenous injection, intraperitoneal injection, intramuscular injection, intratumoral injection, subcutaneous injection, intradermal injection, intraventricular injection, intravascular injection, intracerebellar injection, intraocular injection, subretinal injection, intravitreal injection, intracameral injection, intratympanic injection, intranasal administration, and inhalation.

[0360] In some embodiments, the method for targeting RNA results in editing the sequence of the target RNA. For example, by using a Cas13 protein or fusion protein with a non-mutated HEPN domain and a guidance polynucleotide comprising a guide sequence specific to the target RNA, the target RNA can be cut at a precise position or the target RNA can be formed into a nick (nick, for example, when the target RNA exists as a double-stranded nucleic acid molecule, any single strand thereof is cut). In some instances, this method is used to reduce the expression of the target RNA, which will reduce the translation of the corresponding protein. This method can be used in cells that do not need to increase RNA expression. In one example, RNA is related to diseases such as cystic fibrosis, Huntington's disease, Tay-Sachs, fragile X syndrome, fragile X-related tremor / ataxia syndrome, muscular dystrophy, myotonic dystrophy, spinal muscular atrophy, spinocerebellar ataxia, age-related macular degeneration, or familial ALS. In another example, RNA is related to cancer (for example, lung cancer, breast cancer, colon cancer, liver cancer, pancreatic cancer, prostate cancer, bone cancer, brain cancer, skin cancer (for example, melanoma) or kidney cancer). Examples of target RNAs include, but are not limited to, those associated with cancer (e.g., PD-L1, BCR-ABL, Ras, Raf, p53, BRCA1, BRCA2, CXCR4, β-catenin, HER2, and CDK4). Editing such target RNAs can produce therapeutic effects.

[0361] In some embodiments, RNA is expressed in immune cells. For example, target RNA can encode a protein that causes suppression of a desired immune response (e.g., tumor infiltration). Knocking down this RNA can promote the immune response (e.g., PD1, CTLA4, LAG3, TIM3) required. In another example, target RNA encodes a protein that causes undesirable immune response activation, such as in the case of autoimmune diseases such as multiple sclerosis, Crohn's disease, lupus, or rheumatoid arthritis.

[0362] Diagnostic applications

[0363] Another aspect of the present disclosure relates to an in vitro composition comprising a CRISPR-Cas13 system described herein and a labeled detector RNA that is incapable of hybridizing to a guide polynucleotide described herein.

[0364] Another aspect of the present disclosure relates to the use of the CRISPR-Cas13 system described herein for detecting a target RNA in a nucleic acid sample suspected of containing the target RNA.

[0365] In some embodiments, the method for detecting the target RNA includes a Cas13 protein or fusion protein fused to a fluorescent protein or other detectable label and a guide polynucleotide comprising a guide sequence specific to the target RNA. The binding of the Cas13 protein or fusion protein to the target RNA can be visualized by a microscope or other imaging method. In another example, an RNA aptamer sequence can be attached to or inserted into a guide polynucleotide, such as MS2, PP7, Qβ and other aptamers. Introducing proteins that specifically bind to these aptamers, such as MS2 phage coat proteins fused to fluorescent proteins or other detectable labels can be used to detect target RNA because the Cas13-guide-target RNA complex will be labeled by aptamer interactions.

[0366] In some embodiments, the method for detecting a target RNA in a cell-free system results in the production of a detectable label or enzyme activity. For example, by using a Cas13 protein, a guide polynucleotide comprising a guide sequence specific for the target RNA, and a detectable label, the target RNA will be recognized by Cas13. The binding of Cas13 to the target RNA triggers its RNase activity, which results in the cleavage of the target RNA and the detectable label.

[0367] In some embodiments, the detectable label is an RNA connected to a fluorescent probe and a quencher. Complete detectable RNA connects a fluorescent probe and a quencher to suppress fluorescence. After the detectable RNA is cut by Cas13, the fluorescent probe is released from the quencher and shows fluorescent activity. This method can be used to determine whether the target RNA is present in a cracked cell sample, a cracked tissue sample, a blood sample, a saliva sample, an environmental sample (such as water, soil or air sample) or other cracked cells or cell-free samples. This method can also be used to detect pathogens, such as viruses or bacteria, or to diagnose disease states, such as cancer.

[0368] In some embodiments, the detection of target RNA helps diagnose diseases and / or pathological conditions, or the presence of viral or bacterial infections. For example, Cas13-mediated detection of non-coding RNAs such as PCA3, if detected in patient urine, can be used to diagnose prostate cancer. In another example, Cas13-mediated detection of lncRNA-AA174084, a biomarker for gastric cancer, can be used to diagnose gastric cancer.

[0369] Example

[0370] Experimental Example 1: Screening of C13-2 protein

[0371] 1. CRISPR and gene annotation

[0372] The software was used to predict the proteins of the whole genome of microorganisms from the NCBI Gebank and CNGB (China National Gene Bank) databases, and then the CRISPR array on the genome was predicted using the software.

[0373] 2. Preliminary screening of proteins

[0374] Clustering was used to remove redundant proteins, and proteins with amino acid sequence lengths less than 800 aa (amino acids) or greater than 1400 aa were filtered out.

[0375] 3. Acquisition of CRISPR-related proteins

[0376] The CRISPR array was used to compare protein sequences within 10 kb upstream and downstream of known Cas13s, filtering out proteins with an e-value greater than 1*e-5. Proteins with high similarity were then compared with the NCBI NR library and the EBI patent library, filtering out proteins with high similarity. Finally, candidate proteins were selected. Through experimental verification, the C13-2 protein (SEQ ID NO: 1,893aa) was finally obtained. The C13-2 protein is also known as the CasRfg.4 protein.

[0377] The genomic sequence origin of the C13-2 protein is shown in Table 1 .

[0378] Table 1. Source of the genomic sequence of the C13-2 protein.

[0379] The native (wild-type) DNA coding sequence of the C13-2 protein is SEQ ID NO:9.

[0380] The locus structure of the C13-2 protein is shown in Figure 1 , which includes the CRISPR array and the C13-2 coding sequence.

[0381] The direct repeat (DR) sequence or scaffold sequence of the gRNA used in combination with C13-2 can be:

[0382] 5'-GGAAGAUAACUCUACAAACCUGUAGGGUUCUGAGAC-3' (SEQ ID NO: 3).

[0383] The RNA secondary structure of the above-mentioned direct repeat sequence predicted by RNAfold is shown in Figure 2.

[0384] Experimental Example 2: Preparation, Isolation and Purification of C13-2 Protein

[0385] (1) Vector construction

[0386] 1. Take the pET28a vector plasmid, double-digest it with BamHI and XhoI, and then recover the linearized vector by agarose gel electrophoresis. Insert the DNA fragment containing the protein coding sequence (encoding C13-2 protein and nuclear localization signal) into the cloning region of the pET28a vector by homologous recombination. Transform the reaction solution into Stbl3 competent cells, spread on kanamycin sulfate-resistant LB plates, and culture overnight at 37°C. Then, select clones for sequencing and identification.

[0387] The constructed recombinant vector was named C13-2-pET28a (SEQ ID NO: 10), which was used to express the C13-2 recombinant protein (SEQ ID NO: 11). The C13-2 recombinant protein structure was His tag-NLS-Cas13-SV40 NLS-nucleoplasmin NLS.

[0388] 2. Culture the positive clones with the correct sequence overnight, extract the plasmid and transform it into the expression strain RIPL-BL21 (DE3), spread it on the kanamycin sulfate resistance LB plate, and culture it at 37°C overnight.

[0389] (2) Protein expression

[0390] 1. Pick a single clone and inoculate it into 5 ml of LB culture medium containing kanamycin sulfate resistance and culture it at 37℃ overnight.

[0391] 2. Inoculate 500 ml of kanamycin sulfate-resistant TB culture medium at a volume ratio of 1:100, culture at 220 rpm and 37°C until the OD value reaches 0.6, add IPTG to a final concentration of 0.2 mM, and induce at 16°C for 24 h.

[0392] 3. Collect the cells by centrifugation. Rinse the cells with 15 ml of PBS and then collect the cells by centrifugation. Add lysis buffer and ultrasonically disrupt the cells. Centrifuge at 10,000 g for 30 min to obtain the supernatant containing the recombinant protein. Filter the supernatant through a 0.45 μm filter membrane and then apply it to the column for purification.

[0393] (III) Protein purification

[0394] The purified C13-2 recombinant protein was purified by MAC (Ni Sepharose 6 Fast Flow, CYTIVA) and HITRAP HEPARIN HP (CYTIVA). The purified C13-2 recombinant protein showed a single band on SDS-PAGE electrophoresis (as shown in FIG3 ).

[0395] Experimental Example 3: Verification of exogenous gene editing efficiency

[0396] 1. Synthesize the EGFP-targeted vector to be verified and the control vector

[0397] The sequence of the synthetic exogenous EGFP expression vector is shown in SEQ ID NO: 13, and the plasmid structure is CMV-EGFP. The verification vector plasmid for synthesizing the C13-2 protein targeting EGFP is shown in SEQ ID NO: 14, and the plasmid structure is CMV-C13-2-U6-gRNA.

[0398] EGFP was used as an exogenous reporter gene, and its nucleic acid sequence (720 bp) is shown in SEQ ID NO:12.

[0399] The guide sequence targeting EGFP is ugccguucuucugcuugucggccaugauau (SEQ ID NO: 4).

[0400] 2. Transfect 293T cells with the vector to be verified

[0401] The exogenous EGFP expression vector and the C13-2 protein-targeted EGFP verification vector plasmid were transfected into 293T cells in a 24-well plate at a ratio of 1:2 (166 ng:334 ng).

[0402] The transfection method is as follows:

[0403] 1. Digest 293T cells with trypsin (0.25%, EDTA, Thermo, 25200056), count the cells, and add 2×10 5 Cells were plated in 24-well plates.

[0404] 2. For each transfection sample, prepare the complexes as follows:

[0405] a. Add 50 μL of serum-free Opti-MEM I (Thermo, 11058021) reduced serum medium to each well of the 24-well plate containing cells and gently mix.

[0406] b. Gently mix Lipofectamine 2000 (Thermo, 11668019) before use, then dilute 1 μL of Lipofectamine 2000 in 50 μL of Opti-MEM I medium per well. Incubate at room temperature for 5 minutes. Note: Proceed to step c within 25 minutes.

[0407] c. After a 5-minute incubation, combine the diluted DNA with diluted Lipofectamine 2000. Mix gently and incubate at room temperature for 20 minutes (the solution may appear turbid). Note: The complex is stable at room temperature for 6 hours. Add the complex to 293T cells and mix. Detect the complex by flow cytometry 48 hours later.

[0408] 3. Flow cytometry detection of the effect of downregulating EGFP expression

[0409] The cells and plasmids used are shown in Table 2:

[0410] Table 2. Experimental groups

[0411] 48 h after transfection, cells were digested with trypsin (0.25%, EDTA, Thermo), centrifuged at 300g for 5 min to remove the supernatant, and cells in each well were resuspended in 500 μL of PBS. EGFP fluorescence expression was detected by flow cytometry. After removing cell debris by FCS-A and SSC-A gating, data were collected by flow cytometry.

[0412] Collect and record the Mean-FITC-A results of the FITC channel, and calculate the downregulation amplitude according to the following formula:

[0413] Let the GFP fluorescence of the EGFP group be a, and the GFP fluorescence of the other groups be x. Downregulation (%) = (ax) ÷ a × 100. The blank control group was not included in the comparison. The downregulation results are shown in Table 3. C13-2 targeting EGFP downregulated its expression by 64.49%.

[0414] Table 3. GFP fluorescence detection results by flow cytometry

[0415] Experimental Example 4: Verification of Endogenous Gene Editing Efficiency

[0416] 1. Construction of vectors targeting AQp1 and PTBP1

[0417] The expression vector C13-2-BsaI plasmid was synthesized, and its sequence is shown in SEQ ID NO:15.

[0418] The target nucleic acids selected for the experiment were AQp1 (Aquaporin 1) and PTBP1 (Polypyrimidine Tract Binding Protein 1). AQp1 was verified using the 293T cell line that highly expresses AQp1, and PTBP1 was verified using the 293T cell line.

[0419] Method for constructing a 293T cell line overexpressing AQp1 (293T-AQp1 cells): A vector overexpressing the AQp1 and EGFP genes, Lv-AQp1-T2a-GFP (SEQ ID NO: 16), was constructed. AQp1 and EGFP were separated by a 2A peptide. The Lv-AQp1-T2a-GFP plasmid was packaged into lentiviral vectors and transduced into 293T cells to establish a cell line stably overexpressing the AQp1 gene.

[0420] The gRNA guide sequence targeting AQp1 is:

[0421] AGGGCAGAACCGAUGCUGAUGAAGAC (SEQ ID NO: 5).

[0422] The gRNA guide sequence targeting PTBP1 is:

[0423] GUGGUUGGAGAACUGGAUGUAGAUGGGCCUG (SEQ ID NO: 6).

[0424] Primer annealing was used to obtain fragments targeting the target site. The primers are as follows:

[0425] Targeting PTBP1

[0426] Upstream primer: 5'-AGACGTGGTTGGAGAACTGGATGTAGATGGGCTG-3' (SEQ ID NO: 22)

[0427] Downstream primer: 5'-AAAACAGCCCATCTACATCCAGTTCTCCAACCAC-3' (SEQ ID NO: 23)

[0428] Targeting AQp1

[0429] Upstream primer: 5'-AGACAGGGCAGAACCGATGCTGATGAAGAC-3' (SEQ ID NO: 24)

[0430] Downstream primer: 5'-AAAAGTCTTCATCAGCATCGGTTCTGCCCT-3' (SEQ ID NO: 25)

[0431] The primer annealing reaction system is shown in the table below. Incubate at 95°C in a PCR instrument for 5 minutes, then immediately remove and incubate on ice for 5 minutes to allow the primers to anneal to each other to form double-stranded DNA with sticky ends.

[0432] The synthesized C13-2-BsaI vector plasmid was digested with Bsa I endonuclease. The annealed product and the purified backbone recovered after digestion were ligated using T4 DNA ligase. After transformation into E. coli, positive clones were selected and plasmids were extracted to obtain the C13-2 vector (C13-2 targeting AQP1 or PTBP1) for use in the following C13-2 experimental group. The C13-2 vector construct is CMV-C13-2-U6-gRNA, and can be used to express the C13-2 protein and gRNA targeting AQp1 or PTBP1.

[0433] The following control vectors were prepared using conventional methods:

[0434] The sequence of the CasRx-AQp1 plasmid (a positive control vector for CasRx targeting AQp1) is shown in SEQ ID NO: 17, and the plasmid structure is CMV-CasRx-U6-gRNA, which contains a sequence encoding CasRx (amino acid sequence shown in SEQ ID NO: 2).

[0435] The sequence of the shRNA-AQp1 plasmid (positive control vector for shRNA targeting AQp1) is shown in SEQ ID NO: 19, and is used to express shRNA molecules. The shRNA molecule sequence is CCACGACCCUCUUUGUCUUCACUCGAGUGAAGACAAAGAGGGUCGUGG (SEQ ID NO: 7).

[0436] The sequence of the shRNA-PTBP1 plasmid (positive control vector for shRNA targeting PTBP1) is shown in SEQ ID NO: 20, and is used to express shRNA molecules. The shRNA molecule sequence is CAGCCCAUCUACAUCCAGUUCCUCGAGGAACUGGAUGUAGAUGGGCUG (SEQ ID NO: 8).

[0437] The sequence of the CasRx-blank plasmid (blank control vector, which can express CasRx and gRNA, but the gRNA does not target AQp1 and PTBP1) is shown in SEQ ID NO: 21, and the plasmid structure is CMV-CasRx-U6-gRNA.

[0438] 2. Transfect 293T cells and 293T-AQp1 cells with the vector to be verified

[0439] 293T-AQp1 cells were transfected with 500 ng of the control plasmid or the vector plasmid targeting AQP1 in a 24-well plate. 293T cells were transfected with 500 ng of the control plasmid or the vector plasmid targeting PTBP1 in a 24-well plate.

[0440] The transfection method is as follows:

[0441] 1. Digest the cells with trypsin (0.25%, EDTA, Thermo), count the cells, and add 2×10 5 Cells were plated in 24-well plates.

[0442] 2. For each transfection sample, prepare the complexes as follows:

[0443] a. Add 50 μL of serum-free Opti-MEM I (Thermo) reduced serum medium to each well of the 24-well plate containing cells and dilute the aforementioned plasmid DNA and mix gently.

[0444] b. Gently mix Lipofectamine 2000 (Thermo, 11668019) before use, then dilute 1.8 μL of Lipofectamine 2000 in 50 μL of Opti-MEM I medium per well. Incubate at room temperature for 5 minutes. Note: Proceed to step c within 25 minutes.

[0445] c. After a 5-minute incubation, combine the diluted DNA with the diluted Lipofectamine 2000. Mix gently and incubate at room temperature for 20 minutes (the solution may appear turbid). Note: The complex is stable at room temperature for 6 hours.

[0446] The complexes were added to the cells and mixed.

[0447] 3. qPCR detection of target gene RNA

[0448] 48 hours after transfection, RNA was extracted from cells using the SteadyPure Universal RNA Extraction Kit AG21017, and RNA concentration was measured using an ultra-micro-spectrophotometer. RNA products were reverse transcribed using the Evo M-MLV Mix Kit with gDNA Clean for qPCR Reverse Transcription Kit and detected using the SYBR Green Premix Pro Taq HS qPCR Kit.

[0449] The primers used in qPCR are as follows:

[0450] Detection of PTBP1:

[0451] Upstream primer: 5'-ATTGTCCCAGATATAGCCGTTG-3' (SEQ ID NO: 26)

[0452] Downstream primer: 5'-GCTGTCATTTCCGTTTGCTG-3' (SEQ ID NO: 27)

[0453] Detection of AQp1:

[0454] Upstream primer: 5'-GCTCTTCTGGAGGGCAGTGG-3' (SEQ ID NO: 28)

[0455] Downstream primer: 5'-CAGTGTGACAGCCGGGTTGAG-3' (SEQ ID NO: 29)

[0456] Detection of internal reference GAPDH:

[0457] Upstream primer: 5'-CCATGGGGAAGGTGAAGGTC-3' (SEQ ID NO: 30)

[0458] Downstream primer: 5'-GAAGGGGTCATTGATGGCAAC-3' (SEQ ID NO: 31)

[0459] The reaction system was prepared according to the instructions of SYBR Green Premix Pro Taq HS qPCR Kit and the quantitation was performed using QuantStudio TM 5. Detection was performed using the Real-Time PCR System.

[0460] This experiment used the relative quantification method, 2 -△△Ct The target RNA is calculated by the following method:

[0461] △Ct=Ct(AQp1)-Ct(GAPDH) or Ct(PTBP1)-Ct(GAPDH)

[0462] △△Ct=△Ct(sample to be verified, such as C13-2)-△Ct(CasRx-blank or C13-2-BsaI)

[0463] 2 -△△Ct =2^(-△△Ct)

[0464] The RNA levels of AQp1 and PTBP1 were calculated using the above calculation method. The results of the validation experiment targeting PTBP1 are shown in Table 4 and Figure 4. For the validation of targeting AQp1, three independent biological replicates were performed (transfection procedures using the same batch of 293T cells), and the average results of the three replicates are shown in Table 5 and Figure 5.

[0465] Table 4. PTBP1 RNA knockdown test results

[0466] Table 5. AQp1 RNA knockdown test results

[0467] Note: “-” means not tested.

[0468] C13-2-BsaI and CasRx-blank served as control groups, which do not target either AQp1 or PTBP1. The experimental results showed that when combined with the gRNA used in this experiment, C13-2 exhibited significant editing activity, with high editing activity targeting PTBP1 and higher editing activity targeting AQp1 than CasRx.

[0469] Experimental Example 5: Comparison of editing efficiency with published Cas13 proteins

[0470] 1. Construction of an editing vector targeting the endogenous gene PTBP1

[0471] Patent publication number US10476825B2 discloses the Cas13 protein from BMZ-11B_GL0037771, which is referred to as C13-113 in this experimental example (the amino acid sequence of the protein is shown in SEQ ID NO: 32). The direct repeat sequence corresponding to C13-113 used in this experimental example is shown in SEQ ID NO: 33.

[0472] GenBank discloses the Cas13 protein MBR0191107.1, which is referred to as C13-114 in this application (the amino acid sequence of the protein is shown in SEQ ID NO: 34). The direct repeat sequence corresponding to C13-114 used in this experimental example is shown in SEQ ID NO: 35.

[0473] The C13-113 and C13-114 expression vectors C13-113-BsaI (SEQ ID NO: 36) and C13-114-BsaI (SEQ ID NO: 37) were synthesized at a reagent company, respectively.

[0474] According to the method of Experimental Example 4, a primer annealing method was used to obtain a fragment targeting the target site, and the primers were as follows:

[0475] Targeting PTBP1

[0476] C13-113:

[0477] Upstream primer: 5'-CAACGTGGTTGGAGAACTGGATGTAGATGGGCTG-3' (SEQ ID NO: 38)

[0478] Downstream primer: 5'-AAAACAGCCCATCTACATCCAGTTCTCCAACCAC-3' (SEQ ID NO: 23)

[0479] C13-114:

[0480] Upstream primer: 5'-atctGTGGTTGGAGAACTGGATGTAGATGGGCTG-3' (SEQ ID NO: 39)

[0481] Downstream primer: 5'-AAAACAGCCCATCTACATCCAGTTCTCCAACCAC-3' (SEQ ID NO: 23)

[0482] According to the method of Experimental Example 4, the synthesized C13-113-BsaI and C13-114-BsaI plasmids were digested with BsaI endonuclease, and then T4 ligated with the annealed product. After transformation into E. coli, positive clones were selected and plasmids were extracted. 293T cells (293T cells from different batches than Experimental Example 4) were transfected and tested 72 hours later. The blank control group was transfected with C13-2-BsaI of Experimental Example 4.

[0483] 72 hours after transfection, RNA was extracted from the cells, reverse transcribed, and qPCR was performed according to the method of Experimental Example 4 (primers were the same as those in Experimental Example 4).

[0484] according to Green Premix Pro Taq HS qPCR Kit Instructions: Configure the reaction system and use QuantStudio TM 5Real-Time PCR System was used for detection.

[0485] Use 2 -△△Ct The amount of PTBP1 RNA was calculated using the following method:

[0486] ΔCt=Ct(PTBP1)-Ct(GAPDH)

[0487] △△Ct=△Ct(sample to be verified)-△Ct(C13-2-BsaI)

[0488] 2 -△△Ct =2^(-△△Ct)

[0489] The experimental results are shown in Table 6 and Figure 6.

[0490] Table 6. Comparison of PTBP1 RNA knockdown test results

[0491] The data in the table show that when combined with the gRNA targeting PTBP1 in this experimental example, C13-2 achieved higher editing efficiency, surpassing that of C13-113 and C13-114. No significant editing was observed in the C13-113 group.

[0492] Experimental Example 6: Testing the off-target effect of C13-2

[0493] The EMBOSS-water program and the NCBI-Blast program were used to predict the whole genome and full cDNA sequence of the target species (Homo sapiens). The forward and reverse strands of the gRNA guide sequence were used for comparison. The prediction results were filtered according to the difference between the predicted target and the gRNA guide sequence length not exceeding four bases and the mismatch + gap not exceeding four bases. The potential off-target information was obtained as shown in Table 7.

[0494] Table 7. Number of predicted potential off-target genes

[0495] The C13-2 PTBP1-targeting vector plasmid, shRNA-PTBP1 plasmid (the shRNA expressed by it is referred to as "shRNA2" in this experimental example), and CasRx-blank plasmid of Experimental Example 4 were used.

[0496] The CasRx-PTBP1 plasmid (positive control vector for CasRx targeting PTBP1) was prepared using conventional methods. The sequence is shown in SEQ ID NO: 18, and the plasmid structure is CMV-CasRx-U6-gRNA.

[0497] According to the method of Experimental Example 4, a plasmid expressing shRNA1 was constructed (the difference from the shRNA-PTBP1 plasmid is only that the guide sequence of the encoded shRNA is different, but it also targets PTBP1, and no additional g is added after the U6 promoter).

[0498] The above plasmids were transfected into 293T cells according to the method of Experimental Example 4. 24-well plates were transfected according to the instructions of Lipofectamine 2000 (Thermo). RNA was extracted using the SteadyPure Universal RNA Extraction Kit AG21017 72 hours later.

[0499] Extracted RNA samples were sequenced using PE150bp RNA-Seq. The resulting fastq files were aligned with the target species reference genome using HISAT or STAR software to generate aligned BAM files. Transcripts and gene expression levels were then determined using Kallisto, RSEM, or HTSeq.

[0500] DESeq2, limma-voom, and edger were used to perform differential expression analysis of each group (relative to the CasRx-blank group). Genes with p.adj < 0.05, |log2FoldChange| > = 0.5, and basemean > 2.5 were considered differentially expressed genes (DEGs). The following DEG information was obtained:

[0501] Table 8. Number of differentially expressed genes and their intersection with predicted potential off-target genes

[0502] Note: Up indicates up-regulation of expression, and Down indicates down-regulation of expression.

[0503] Sig represents a significant difference in gene expression compared with the control group (CasRx-blank group).

[0504] Isec represents the number of DEGs intersected with the “potential off-target genes” predicted by the program.

[0505] As can be seen from the data in the table above, the number of off-target sites after the intersection of transcriptome sequencing and predicted off-targets for CasRx and C13-2 is zero. C13-2 has almost no off-targets, while shRNA1 and shRNA2 have a large number of off-target sites. In terms of off-target safety, C13-2 is superior to shRNA1 and shRNA2 and comparable to CasRx. In addition, C13-2 is only 893 aa in size, much smaller than CasRx's 967 aa, making it easier to package with gRNA into AAV for delivery.

[0506] Experimental Example 7: Targeted Editing of ANGPTL3

[0507] This experimental example refers to the method of Experimental Example 4.

[0508] A vector Lv-ANGPTL3-T2a-GFP (SEQ ID NO: 52) was constructed to overexpress the ANGPTL3 and EGFP genes, wherein ANGPTL3 and EGFP were separated by a 2A peptide. The Lv-ANGPTL3-T2a-GFP plasmid was packaged into lentivirus and transduced into 293T cells to obtain a 293T cell line stably overexpressing the ANGPTL3 gene (referred to as 293T-ANGPTL3 cells).

[0509] Primer annealing is used to obtain fragments targeting the target site.

[0510] The C13-2-BsaI vector (SEQ ID NO: 15) was digested with Bsa I endonuclease, and the annealed product and the purified backbone recovered after digestion were ligated by T4 ligation. After transformation into E. coli, positive clones were selected and extracted to obtain a C13-2 plasmid targeting ANGPTL3 (CMV drives C13-2 protein expression, the U6 promoter drives gRNA expression, the gRNA DR sequence is SEQ ID NO: 3, and the gRNA guide sequence is shown in Table 9). The plasmid was then transfected into 293T-ANGPTL3 cells. A negative control group was transfected with the C13-2-BsaI plasmid.

[0511] Table 9. gRNA guide sequences targeting ANGPTL3 RNA

[0512] 72 h after transfection, RNA was extracted and reverse transcribed, and the reverse transcription products were detected by qPCR.

[0513] The primers used for qPCR are as follows:

[0514] Detection of ANGPTL3:

[0515] Upstream primer: 5'-CCAGAACACCCAGAAGTAACT-3' (SEQ ID NO: 50)

[0516] Downstream primer: 5'-TCTGTGGGTTCTTGAATACTAGTC-3' (SEQ ID NO: 51)

[0517] Detection of internal reference GAPDH:

[0518] Upstream primer: 5'-CCATGGGGAAGGTGAAGGTC-3' (SEQ ID NO: 30)

[0519] Downstream primer: 5'-GAAGGGGTCATTGATGGCAAC-3' (SEQ ID NO: 31)

[0520] Using relative quantification method 2 -△△Ct The target RNA content was calculated using the target RNA analysis method. Recombinant plasmid transfection, RNA extraction, reverse transcription, and qPCR were performed in three independent biological replicates, and the average results of the three replicates were obtained. These results are shown in Table 10 and Figure 7.

[0521] Table 10. ANGPTL3 RNA knockdown test results

[0522] Experimental data showed that C13-2 can effectively knock down ANGPTL3 RNA, among which gRNA2, gRNA4, gRNA5, and gRNA6 had significant editing effects.

[0523] Experimental Example 8: Editing using the C13-2 inactivated mutant (dC13-2)

[0524] A C13-2-VEGFA vector (SEQ ID NO: 72) was constructed, which can express C13-2 protein and gRNA targeting VEGFA, and the gRNA guide sequence is TGGGTGCAGCCTGGGACCACTTGGCATGG (SEQ ID NO: 73).

[0525] Then, conventional homologous recombination methods were used to construct the C13-2-VEGFA vector to obtain the C13-2 R4xH mutant verification vector, as shown in Table 11.

[0526] The mutant vector introduced the following mutations relative to the C13-2 coding sequence of the C13-2-VEGFA vector:

[0527] R210A+H215A: AGAAACGCCACCGCCCAC(SEQ ID NO:74)→GCAAACGCCACCGCCGCC(SEQ ID NO:75);

[0528] R750A+H755A: AGAAAGACCAAGAGACAC (SEQ ID NO: 76) → GCAAGACCAAGAGAGCC (SEQ ID NO: 77); and / or

[0529] R785A+H790A: AGAAACGACGTGGAGCAC (SEQ ID NO:78)→GAAAACGACGTGGAGGCC (SEQ ID NO:79).

[0530] Table 11. Vectors used to test C13-2 inactivating mutations

[0531] The vector was transfected into a 293T cell line. Transfection was performed according to the instructions for Lipofectamine 2000 (Thermo). RNA was extracted 72 hours later using the SteadyPure Universal RNA Extraction Kit. RNA extracted from three batches of the experiment was sent to a sequencing company for RNAseq sequencing. The amount of VEGFA RNA detected is shown in Table 12 below:

[0532] Table 12. VEGFA RNA amount determined by RNAseq sequencing

[0533] The experimental data in Table 12 show that the editing activity remains high after the introduction of the R750A+H755A mutation, and weaker editing activity is retained after the introduction of the R210A+H215A and / or R785A+H790A mutations. The editing activity is almost completely lost only after the introduction of the R210A+H215A, R750A+H755A, and R785A+H790A mutations.

[0534] Experimental Example 9: Testing of C13-2 Truncated Body

[0535] Construction of a validation vector targeting the C13-2 truncation of the endogenous gene VEGFA

[0536] Using the three-fragment homologous recombination method, the verification vectors of each truncation shown in Table 13 were constructed from the C13-2-VEGFA plasmid (SEQ ID NO: 72) (the only difference from the C13-2-VEGFA vector is that the coding sequence of C13-2 is truncated), which can express each truncated protein, as well as gRNA targeting VEGFA.

[0537] Table 13. Constructed verification vectors of C13-2 truncations

[0538] Following the instructions of Lipofectamine 2000 (Thermo), the validation vector and the control vector were transfected into the 293T cell line. After 72 hours, RNA was extracted using the SteadyPure Universal RNA Extraction Kit and reverse transcribed using the Evo M-MLV Mix Kit with gDNA Clean for qPCR Reverse Transcription Kit. Green Premix Pro Taq HS qPCR Kit Instructions: Configure the reaction system and use QuantStudio TM5. Detection was performed using the Real-Time PCR System.

[0539] The primers used in qPCR are as follows:

[0540] Detection of VEGFA: ACCTCCACCATGCCAAGTGG (SEQ ID NO: 88)

[0541] CAGGGTCTCGATTGGATGGC(SEQ ID NO:89)

[0542] Detection internal reference GAPDH: CCATGGGGAAGGTGAAGGTC (SEQ ID NO: 30)

[0543] GAAGGGGTCATTGATGGCAAC(SEQ ID NO:31)

[0544] Using relative quantification method 2 -△△Ct The target RNA was calculated using the method. Multiple batches of experiments were repeated and the results were averaged. Table 14 shows the average values.

[0545] Table 14. Relative amount of VEGFA RNA after truncated editing

[0546] The C13-2 truncation in this experimental example retains a certain RNA editing activity.

[0547] Experimental Example 10: Testing of different DR (direct repeat) sequences

[0548] Verification vectors encoding different DR sequences (as shown in Table 15) targeting the endogenous genes VEGFA and PTBP1 were constructed (as shown in Table 16).

[0549] Table 15. Different designed DR sequences

[0550] Table 16. Construction of vector plasmids expressing various gRNAs

[0551] The C13-2-VEGFA vector of Experimental Example 8 and the C13-2 PTBP1-targeted vector plasmid of Experimental Example 4 were constructed by conventional methods (only the crRNA expression frame sequence was replaced) to obtain verification vectors expressing various crRNA sequences (5'-guide-DR-3') in Table 16.

[0552] Following the experimental method of the previous example, the validation vector and the control vector were transfected into 293T cells. After 72 hours, RNA was extracted, reverse transcribed, and tested using a qPCR kit. The primers used for qPCR are as follows:

[0553] Detection of VEGFA: ACCTCCACCATGCCAAGTGG (SEQ ID NO: 88)

[0554] CAGGGTCTCGATTGGATGGC(SEQ ID NO:89)

[0555] Detection of PTBP1: ATTGTCCCAGATATAGCCGTTG (SEQ ID NO: 26)

[0556] GCTGTCATTTCCGTTTGCTG(SEQ ID NO:27)

[0557] Detection internal reference GAPDH: CCATGGGGAAGGTGAAGGTC (SEQ ID NO: 30)

[0558] GAAGGGGTCATTGATGGCAAC(SEQ ID NO:31)

[0559] Use 2 -△△Ct The target RNA changes were calculated using the same method. Multiple batches of experiments were repeated, and the results were averaged. These are shown in Tables 17 and 18, and Figures 9 and 10.

[0560] Table 17. Relative amount of VEGFA RNA after editing with different gRNAs

[0561] Table 18. Relative amount of PTBP1 RNA after editing with different gRNAs

[0562] The experimental results in Tables 17 and 18 show that the editing efficiency was highest when using DRrc or DR-hf2, which was superior to other DR sequences (P < 0.05). Relatively high editing efficiency was also achieved when using DR2rc, DR3, or DR4, which was superior to DR2, DR3rc, DR4rc, and DR-hf1.

[0563] The sequence alignment results of the direct repeat sequences DRrc, DR-hf2, and DR2rc are shown in FIG18 .

[0564] The RNA secondary structure of the direct repeat sequence DR-hf2 predicted by RNAfold is shown in FIG19 .

[0565] Experimental Example 11: Comparison of C13-2 and mainstream Cas13 tools

[0566] All verification vectors and control vectors (Table 19) of this experimental example use the same backbone sequence as C13-2-BsaI (SEQ ID NO: 15), with only Cas13 coding sequence and crRNA coding sequence being different. The NLS sequence of each vector and its connecting sequence are identical. All vector structures are CMV-NLS-Cas13-2 × NLS-U6-crRNA, and all Cas13s carry 1 NLS at the N-terminus and 2 NLSs at the C-terminus, for a total of 3 × NLS structures.

[0567] Because 293T cells do not contain EGFP sequences, a vector targeting GFP was used as a negative control.

[0568] The guide sequence targeting GFP was tgccgttcttctgcttgtcggccatgatat (SEQ ID NO: 90).

[0569] The guide sequence targeting PTBP1 is:

[0570] GTGGTTGGAGAACTGGATGTAGATGGGCTG (SEQ ID NO: 6).

[0571] The guide sequence targeting VEGFA is:

[0572] TGGGTGCAGCCTGGGACCACTTGGCATGG (SEQ ID NO:73).

[0573] Table 19. Validation and control vectors constructed for comparison with mainstream Cas13 tools

[0574] To save space, the sequences of four vectors in Table 19 are given as examples (SEQ ID NO: 91-94).

[0575] The validation vector and control vector were transfected into 293T cells. 293T cells not transfected with the plasmid served as a blank control.

[0576] Transfection was performed according to the instructions of Lipofectamine 2000 (Thermo). After 48 h, RNA was extracted using the SteadyPure Universal RNA Extraction Kit and the RNA concentration was measured using an ultra-micro spectrophotometer. The RNA product was reverse transcribed using the Evo M-MLV Mix Kit with gDNA Clean for qPCR reverse transcription kit. Green Premix Pro Taq HS qPCR Kit Instructions: Configure the reaction system and use QuantStudio TM 5. Detection was performed using the Real-Time PCR System.

[0577] The primers used in qPCR are as follows:

[0578] Detection of VEGFA: ACCTCCACCATGCCAAGTGG (SEQ ID NO: 88)

[0579] CAGGGTCTCGATTGGATGGC(SEQ ID NO:89)

[0580] Detection of PTBP1: ATTGTCCCAGATATAGCCGTTG (SEQ ID NO: 26)

[0581] GCTGTCATTTCCGTTTGCTG(SEQ ID NO:27)

[0582] Detection internal reference GAPDH: CCATGGGGAAGGTGAAGGTC (SEQ ID NO: 30)

[0583] GAAGGGGTCATTGATGGCAAC(SEQ ID NO:31)

[0584] Use 2 -△△Ct The amount of target RNA was calculated using the GFP-targeting method. Each Cas13 protein was used as a negative control. Multiple batches of experiments were performed and the results were averaged. As shown in Table 20, Table 21, Figure 11, and Figure 12.

[0585] Table 20. C13-2 and known Cas13 tools targeting VEGFA RNA

[0586] In the comparison of VEGFA target editing effects, C13-2 has a very good editing effect, which is better than the current mainstream Cas13 editing tools. The editing efficiency is C13-2>PspCas13b>Cas13X.1>Cas13Y.1.

[0587] Table 21. C13-2 and known Cas13 tools targeting PTBP1 RNA

[0588] In a comparison of PTBP1 target editing effects, C13-2 performed very well, with the editing efficiency values ​​of C13-2 > CasRx > PspCas13b > Cas13X.1 > Cas13Y.1. The editing efficiency of C13-2 was significantly superior to that of PspCas13b, Cas13X.1, and Cas13Y.1 (P < 0.05).

[0589] Experimental Example 12: Construction of a single-base editor from dC13-2

[0590] In this experimental example, the target used to verify the effect of single-base editing is EGFP, and the guide sequence used to target EGFP is tgccgttcttctgcttgtcggccatgatatagacgttgtggctgttgtagttgtactccagcttgtgccc (SEQ ID NO: 95).

[0591] The vectors used in this experimental example to express dC13-2 all contained inactivated mutants of C13-2 containing R210A+H215A, R750A+H755A, and R785A+H790A mutations.

[0592] Table 22. Plasmid vectors and descriptions related to single-base editing

[0593] The dC13-2-BsaI and dC13-2-EGFP vectors were constructed using conventional methods.

[0594] A single-base editing verification vector was obtained by homologous recombination using dC13-2-BsaI plasmid, dC13-2-EGFP plasmid and pC0055-CMV-dPspCas13b-GS-ADAR2DD plasmid.

[0595] dC13-2-ADAR-EGFP, dC13-2-A(EAAAK)3A-ADAR-EGFP, and dC13-2-(GGGGS)3-ADAR-EGFP.

[0596] pC0055-CMV-dPspCas13b-GS-ADAR2DD was used as a positive control. Since this plasmid does not contain a gRNA expression cassette, the gRNA expression vector PLKO-PURO-PspGRNA-EGFP was synthesized by an outsourced company.

[0597] Transfection was performed according to the instructions of Lipofectamine 2000 (Thermo). The vector to be verified was transfected with the EGFP reporter vector pAAV-CMV-EGFP at a ratio of 4:1. The transfection scheme is shown in Table 23 below. Since pC0055-CMV-dPspCas13b-GS-ADAR2DD and PLKO-PURO-PspGRNA-EGFP-AD express PspCas13b-ADAR protein and gRNA, respectively, 200 ng of each was co-transfected.

[0598] Table 23. Transfection plan for single-base editing verification vector and reporter vector

[0599] 48 hours after transfection, RNA was extracted using the SteadyPure Universal RNA Extraction Kit, and RNA concentration was measured using an ultra-micro-spectrophotometer. The RNA product was reverse transcribed using the Evo M-MLV RT-PCR Universal Reverse Transcriptase Kit. PCR was performed using the identified primers, and the PCR product was sequenced by a sequencing company.

[0600] The identification primer sequences are as follows (product length 704 bp):

[0601] agggcgaggagctgtt(SEQ ID NO:103),

[0602] gtacagctcgtccatgccg (SEQ ID NO: 104).

[0603] The sequencing results are shown in Figure 13. The 48th base of the guide sequence produced an A→G conversion at the corresponding position on the target RNA, indicating that the dC13-2 editor constructed by the inventors successfully induced single-base editing.

[0604] The negative control dC13-2-EGFP group did not undergo base transitions, while the positive control dPspCas13b-ADAR group induced base transitions. Base transitions were induced when no linker peptide was used between dC13-2 and ADAR, when a rigid linker peptide A(EAAAK)3A was used, and when a flexible linker peptide (GGGGS)3 was used.

[0605] Experimental Example 13: First round of mutation of C13-2

[0606] Principle of the first round of mutation: AlphaFold v2.1 was used to predict the structure of C13-2, and N→A mutation and R→A mutation were performed on aa 1-89 and aa 263-417 belonging to the REC lobe.

[0607] The designed mutants are shown in Table 24 below.

[0608] Table 24. First round of mutations

[0609] Verification of vector construction

[0610] The first round of mutations was verified using the VEGFA target. The C13-2-VEGFA vector from the previous experimental example was used as the wild-type C13-2 encoding vector and was modified using the Novozymes point mutagenesis kit, Mut Express II Fast Mutagenesis Kit V2, to obtain expression constructs (verification vectors) for each mutant, which were used to express the C13-2 mutant and gRNA targeting VEGFA. The primers used are shown in Table 25 below.

[0611] Table 25. Primer sequences used for vector verification

[0612] Transfection

[0613] The validation and control vectors were transfected into 293T cells according to the instructions for Lipofectamine 2000 (Thermo). The C13-2-BsaI control group was transfected with the C13-2-BsaI vector from the previous experimental example, and the WT control group was transfected with the C13-2-VEGFA vector. Both cells expressed wild-type C13-2. A separate 293T cell control group was established, which was not transfected with any plasmid.

[0614] qPCR detection of target RNA levels

[0615] 48 hours after transfection, RNA was extracted from cells using the SteadyPure Universal RNA Extraction Kit, and RNA concentration was measured using an ultra-micro-spectrophotometer. RNA products were reverse transcribed using the Evo M-MLV Mix Kit with gDNA Clean for qPCR Reverse Transcription Kit and detected using the SYBR Green Premix Pro Taq HS qPCR Kit (Low Rox Plus).

[0616] The primers used in qPCR were SEQ ID NOs: 88, 89, 30, and 31.

[0617] according to Green Premix Pro Taq HS qPCR Kit (Rox Plus) instructions for preparing the reaction system and using QuantStudio TM 5. Detection was performed using the Real-Time PCR System.

[0618] Use 2 -△△Ct The target RNA level after editing was calculated using the same method. The experiment was repeated three times, and the results were averaged, as shown in Table 26 and Figure 14.

[0619] Table 26. qPCR testing of VEGFA RNA levels after mutant targeted editing

[0620] qPCR detection results showed that all point mutants still retained high editing activity.

[0621] RNAseq sequencing

[0622] The total RNA samples extracted after editing were subjected to RNAseq sequencing. The library type was LncRNA chain-specific library, the sequencing data volume was 16G, and the sequencing strategy was PE150.

[0623] RNAseq analysis principle:

[0624] Fastqc and multiqc were used to perform data quality control, and fastp was used to remove low-quality reads;

[0625] The human rRNA sequence was removed and aligned to the hg38 reference genome using Hisat2 alignment software;

[0626] After alignment, Kallisto software was used to quantify gene expression levels, and sleuth software was used to perform differential expression analysis. Genes with |b|>0.5, qval<0.05, and mean_obs>2 were considered differentially expressed genes. The 293T cell control group was used as the benchmark.

[0627] The guide sequence was aligned to the reference cDNA using EMBOSS water software. Transcripts with an aligned base number of ≥18, a mismatched base number of ≤6, and a minimum number of consecutive paired bases of ≥8 were considered predicted off-target transcripts, and the corresponding genes were considered predicted potential off-target genes.

[0628] The intersection of the significantly downregulated differentially expressed genes and the predicted potential off-target genes was taken, and the off-target gene set was obtained after excluding the on-target VEGFA gene.

[0629] RNASeq results analysis

[0630] The VEGFA gene expression levels of each group were analyzed using the 293T cell control group as a benchmark. The results are shown in Table 27 and Figure 15 .

[0631] Table 27. VEGFA editing efficiency measured by RNAseq

[0632] The RNAseq results were basically consistent with the qPCR results.

[0633] When combined with the gRNA of this experimental example, the editing activity of the M02, M07, M08, M10, M12, M14, M15, and M18 variants was slightly improved compared to the wild-type C13-2.

[0634] The number of differentially expressed genes and off-target genes is shown in Table 28.

[0635] Regarding the number of differentially expressed genes that were downregulated in cells after editing, the M04, M09, M17, M22, M25, M27, and M28 groups were less than that in the WT group.

[0636] Regarding the number of off-target genes determined after taking the intersection, groups M01 to M28 were all 0, that is, there was no off-target.

[0637] Table 28. Differentially expressed genes and off-target genes of different mutants targeting VEGFA

[0638] Experimental Example 14: Second round of mutation of C13-2

[0639] Mutant design

[0640] Based on the results of Experimental Example 1, five mutation sites with low off-target potential (M09 N87A, M17 R308A, M28 N394A, M04 R47A, and M13 R290A) were obtained. These sites were combined internally or with other mutation sites. Conservative mutations at conserved sites were also designed. See Table 29.

[0641] Table 29. Mutants designed in the second round

[0642] Verification of vector construction

[0643] The second round of mutagenesis used the human AR (androgen receptor) target for testing, and the C13-2-AR-h3 plasmid vector (SEQ ID NO: 161, which can express wild-type C13-2 and h3 gRNA targeting AR, and its guide sequence is SEQ ID NO: 162, i.e., ATAACATTTCCGAAGACGACAAGAT) was synthesized.

[0644] The C13-2-AR-h3 plasmid vector was modified using the Novozymes point mutagenesis kit Mut Express MultiS Fast Mutagenesis Kit V2 to obtain expression constructs (verification vectors) for each mutant, which were used to express the C13-2 mutant and h3 gRNA. The primers used are shown in Table 30 below.

[0645] Table 30. Primers used to construct mutant expression vectors

[0646] Transfection

[0647] The validation and control vectors were transfected into 293T cells according to the instructions for Lipofectamine 2000 (Thermo). The C13-2-BsaI control group was transfected with the C13-2-BsaI vector from the previous experimental example, and the WT control group was transfected with the C13-2-AR-h3 vector. Both cells expressed wild-type C13-2. A separate 293T cell control group was established, which was not transfected with any plasmid.

[0648] qPCR detection of target RNA levels

[0649] 48 hours after transfection, RNA was extracted from cells using the SteadyPure Universal RNA Extraction Kit, and RNA concentration was measured using an ultra-micro-spectrophotometer. RNA products were reverse transcribed using the Evo M-MLV Mix Kit with gDNA Clean for qPCR Reverse Transcription Kit and detected using the SYBR Green Premix Pro Taq HS qPCR Kit (Low Rox Plus).

[0650] The primers used in qPCR are as follows:

[0651] Detection AR: CCAGGGACCATGTTTTGCC (SEQ ID NO: 275)

[0652] CGAAGACGACAAGATGGACAA(SEQ ID NO:276)

[0653] Detection internal reference GAPDH: SEQ ID NO: 30, 31.

[0654] according to Green Premix Pro Taq HS qPCR Kit (Rox Plus) instructions for preparing the reaction system and using QuantStudio TM 5. Detection was performed using the Real-Time PCR System.

[0655] Use 2 -△△Ct The target RNA level after editing was calculated using the same method. The experiment was repeated three times, and the results were averaged, as shown in Table 31 and Figure 16.

[0656] Table 31. qPCR testing of AR RNA levels after mutant targeted editing

[0657] RNAseq sequencing

[0658] The total RNA samples extracted after editing were subjected to RNAseq sequencing. The library type was LncRNA chain-specific library, the sequencing data volume was 16G, and the sequencing strategy was PE150.

[0659] RNAseq analysis principle:

[0660] Fastqc and multiqc were used to perform data quality control, and fastp was used to remove low-quality reads;

[0661] Sequences aligned to human rRNA were removed and aligned to the hg38 reference genome using Hisat2;

[0662] After alignment, Kallisto software was used to quantify gene expression levels, and sleuth software was used to perform differential expression analysis. Genes with |b|>0.5, qval<0.05, and mean_obs>2 were considered differentially expressed genes;

[0663] The guide sequence was aligned to the reference cDNA using EMBOSS water software, and transcripts with an aligned base number >= 18, a mismatched base number <= 6, and a minimum number of consecutive paired bases >= 8 were considered predicted off-target transcripts, and the corresponding genes were considered predicted off-target genes;

[0664] The intersection of the significantly downregulated differentially expressed genes and the predicted off-target genes was taken, and the on-target AR gene was eliminated to obtain the off-target gene set.

[0665] RNASeq result analysis

[0666] Using the 293T cell control group as a benchmark, the AR gene expression level and editing efficiency (average value) of each group were analyzed. The results are shown in Table 32 and Figure 17.

[0667] Table 32. AR editing efficiency measured by RNAseq

[0668] The RNAseq results were basically consistent with the qPCR results.

[0669] When combined with the gRNA of this experimental example, the editing activity of the M2-1, M2-2, M2-3, M2-4, M2-9, M2-10, M2-16, M2-17, M2-18, M2-19, M2-23, M2-24, M2-25, M2-26, M2-32, M2-33, M2-34, M2-35, M2-39, M2-40 and M2-41 variants was higher than that of the wild-type C13-2.

[0670] The number of differentially expressed genes and off-target genes is shown in Table 33.

[0671] Regarding the number of differentially expressed genes downregulated in cells after editing, the M2-1, M2-2, M2-3, M2-4, M2-5, M2-6, M2-7, M2-8, M2-10, M2-13, M2-14, M2-15, M2-16, M2-21, M2-22, M2-23, M2-24, M2-25, M2-26, M2-27, M2-28, M2-29, M2-30, M2-31, M2-32, M2-33, M2-34, M2-35, M2-36, M2-37, M2-38, M2-39, M2-40, and M2-41 groups were less than those in the WT group.

[0672] Regarding the number of off-target genes identified after taking the intersection, the M2-1, M2-2, M2-3, M2-4, M2-5, M2-6, M2-7, M2-8, M2-10, M2-13, M2-14, M2-15, M2-16, M2-21, M2-22, M2-23, M2-24, M2-25, M2-26, M2-27, M2-28, M2-29, M2-30, M2-31, M2-32, M2-33, M2-35, M2-36, M2-37, M2-38, M2-39, M2-40, and M2-41 groups were less than those in the WT group. Among them, M2-1, M2-6, M2-7, M2-14, M2-15, M2-22, M2-31, M2-38, and M2-39 had no off-target effects.

[0673] Table 33. Differentially expressed genes and off-target genes when mutants target AR

[0674] Experimental Example 15: Testing of target protein levels

[0675] 293T cells were transfected with the C13-2-VEGFA vector from the previous experimental example and the negative control vector C13-2-BsaI (Lipofectamine 2000, Thermo Fisher). The cells were cultured at 37°C for 72 hours, and the supernatant was collected. VEGFA protein levels were assessed using the Elascience Human VEGF-A (Vascular Endothelial Cell Growth Factor A) ELISA Kit, demonstrating a 97.4% decrease in VEGFA protein expression compared to the negative control.

[0676] In 293T cells, editing with a vector expressing CasRx and a gRNA containing the same guide sequence resulted in a 75.7% decrease in VEGFA protein expression compared to the CasRx negative control group.

Claims

1. A Cas13 protein, characterized in that Its amino acid sequence has at least 90% sequence identity compared to SEQ ID NO:

1.

2. The Cas13 protein according to claim 1, wherein The Cas13 protein is capable of forming a CRISPR complex with a guide polynucleotide comprising a direct repeat sequence linked to a guide sequence engineered to direct sequence-specific binding of the CRISPR complex to a target RNA.

3. The Cas13 protein according to claim 1, wherein The Cas13 protein comprises one or more mutations in the catalytic domain and has reduced RNA cleavage activity.

4. The Cas13 protein according to claim 1, wherein The Cas13 protein comprises one or more mutations in one or both HEPN domains and substantially lacks RNA cleavage activity.

5. The Cas13 protein according to claim 1, wherein It has a sequence identity of at least 95%, at least 96%, at least 97%, at least 98% or at least 99% compared to SEQ ID NO:

1.

6. The Cas13 protein according to claim 1, wherein The Cas13 protein comprises at least one mutation at positions corresponding to amino acid residues 40-91, 146-153, 158-176, 182-209, 216-253, 271-287, 341-353, 379-424, 456-477, 521-557, 575-588, 609-625, 700-721, 724-783, 796-815, 828-852, or 880-893 of a reference protein with an amino acid sequence as shown in SEQ ID NO: 1; and / or, The Cas13 protein comprises any one or more mutations at positions corresponding to the following amino acid residues of the reference protein as shown in SEQ ID NO: 1: R11, N34, R35, R47, R58, R63, R64, N68, N87, N265, N274, R276, R290, R294, N299, N303, R308, R314, R320, R328, N332, R341, N346, R358, N372, N383, N390, N394, R47+R290, R47+R314, R290+R314, R47+R290+R314, R308+N6 8. N394+N68, N87+N68, R308+N265, N394+N265, N87+N265, R308+N68+N265, N87+N68+N265, T7, A16, S260, A263, M266, N274, F288, M302, N303, L304, V305, I311, D313, H324, P326, H327, N332, N346, T353, T360, E365, A373, M380, S382, K395, Y396, D402, D411, and S418; Preferably, the mutation is R11A, N34A, R35A, R47A, R58A, R63A, R64A, N68A, N87A, N265A, N274A, R276A, R290A, R294A, N299A, N303A, R308A, R314A, R320A, R328A, N332A, R341A, N346A, R358A, N372A, N383A, N390A, N394A, R47A+R290A, R47A+R314A, R290A+R314A, R47A +R290A+R314A, R308A+N68A, N394A+N68A, N87A+N68A, R308A+N265A, N394A+N265A, N87A+N265A, R308A+N68A+N265A, N87A+N 68A+N265A, T7S, A16S, S260E, A263K, M266I, N274K, F288Y, M302F, N303S, L304I, V305K, I311M, D313E, H324Y, P326S, H327V, N332Y, N346D, T353L, T360S, E365D, A373E, M380K, S382R, K395G, Y396D, D402L, D411E, and S418K.

7. The Cas13 protein according to claim 1, wherein The Cas13 protein comprises any one or more mutations at positions corresponding to the following amino acid residues of the reference protein as shown in SEQ ID NO: 1: N34, R64, N68, N265, R276, R294, N299, R314, R47+R290, R47+R314, R290+R314, R47+R290+R314, N394+N265, N87+N265, A263, M266, N274, F288, V305, I311, D313, H324, T360, E365, A373, M380, D402 and D411; Preferably, the mutations are N34A, R64A, N68A, N265A, R276A, R294A, N299A, R314A, R47A+R290A, R47A+R314A, R290A+R314A, R47A+R290A+R314A, N394A+N265A, N87A+N265A, A263K, M266I, N274K, F288Y, V305K, I311M, D313E, H324Y, T360S, E365D, A373E, M380K, D402L and D411E.

8. The Cas13 protein according to any one of claims 1 to 7, characterized in that The Cas13 protein is from a species comprising a genome having an average nucleotide identity (ANI) ≥ 95% with the genome numbered CNA0009596 in the CNGB database (China National Gene Bank).

9. A fusion protein, characterized in that It comprises the Cas13 protein or its functional fragment according to any one of claims 1 to 8 fused to a protein domain and / or a polypeptide tag; optionally, the original function of the Cas13 protein and / or functional fragment is not changed after fusion.

10. The fusion protein according to claim 9, characterized in that The Cas13 protein or its functional fragment is fused with a nuclear localization signal (NLS).

11. The fusion protein according to claim 9, characterized in that The Cas13 protein or its functional fragment is fused with a nuclear export signal (NES).

12. The fusion protein according to claim 9, characterized in that The Cas13 protein or its functional fragment is covalently linked to the protein domain.

13. The fusion protein according to claim 9, characterized in that The Cas13 protein or its functional fragment is fused to any one or more protein domains and / or polypeptide tags selected from the following: cytosine deaminase domain, adenosine deaminase domain, translation activation domain, translation inhibition domain, RNA methylation domain, RNA demethylation domain, nuclease domain, splicing factor domain, reporter domain, affinity domain, subcellular localization signal, reporter tag and affinity tag.

14. The fusion protein according to any one of claims 9 to 13, characterized in that The structure of the fusion protein is NLS-Cas13 protein-SV40 NLS-nucleoplasmin NLS.

15. A guide polynucleotide, characterized in that It comprises (i) a direct repeat sequence having at least 50% sequence identity to any one of SEQ ID NO: 3 and SEQ ID NO: 80-87, the direct repeat sequence being linked to (ii) a guide sequence engineered to hybridize with a target RNA, wherein the guide polynucleotide is capable of forming a CRISPR complex with the Cas13 protein and guiding the sequence-specific binding of the CRISPR complex to the target RNA; preferably, the Cas13 protein is Cas13a, Cas13b, Cas13c or Cas13d; more preferably, the Cas13 protein has at least 90%, at least 95%, at least 98% or at least 99% sequence identity compared to the amino acid sequence shown in SEQ ID NO:

1. Optionally, the direct repeat sequence has an A at base 26 corresponding to SEQ ID NO: 3; Optionally, the direct repeat sequence is GGAAGATN1ACTCTACAAACCTGTAGN2GN3N4N5N6N7N8N9N 10 N 11 ; Among them, N1 and N3-N 11 Any one selected from A, C, G, T; N2 is any one selected from A and G; Further optionally, the direct repeat sequence is GGAAGATN 12 ACTCTACAAACCTGTAGN 13 GN 14 N 15 N 16 N 17 N 18 N 19 N 20 N 21 N 22 ; Among them, N 12 、N 13 、N 19 and N 21 Any one selected from A, G, N 14 Any one selected from A, T, N 15 and N 16 Any one selected from C, T, N 17 and N 18 Any one of G, T, N 20 and N 22 Any one selected from C and G.

16. The guiding polynucleotide according to claim 15, wherein The direct repeat sequence has at least 80%, at least 90% or at least 95% sequence identity compared to any one of SEQ ID NOs: 3, 81, 82, 84 and 87.

17. The guiding polynucleotide according to claim 15, wherein The guide sequence is located at the 3' end of the direct repeat sequence.

18. The guiding polynucleotide according to claim 15, wherein The guide sequence comprises 15-35 nucleotides.

19. The guiding polynucleotide according to claim 15, wherein The guide sequence hybridizes to the target RNA with no more than a one nucleotide mismatch.

20. The guiding polynucleotide according to claim 15, wherein The direct repeat sequence comprises 25 to 40 nucleotides.

21. The guiding polynucleotide according to claim 15, wherein The guide polynucleotide further comprises an aptamer sequence.

22. The guiding polynucleotide according to claim 21, wherein The aptamer sequence is inserted into the loop of the guide polynucleotide.

23. The guiding polynucleotide according to claim 21, wherein The aptamer sequence includes an MS2 aptamer sequence, a PP7 aptamer sequence or a Qβ aptamer sequence.

24. The guiding polynucleotide according to claim 15, wherein The guide polynucleotide comprises modified nucleotides.

25. The guiding polynucleotide according to claim 24, wherein The modifications include 2'-O-methyl, 2'-O-methyl-3'-phosphorothioate or 2'-O-methyl-3'-thioPACE modifications.

26. The guiding polynucleotide according to any one of claims 15 to 25, wherein The target RNA is located in the nucleus of a eukaryotic cell.

27. The guiding polynucleotide according to any one of claims 15 to 26, wherein The target RNA is selected from TTR RNA, SOD1 RNA, PCSK9 RNA, VEGFA RNA, VEGFR1 RNA, PTBP1 RNA, AQp1 RNA or ANGPTL3 RNA; preferably, the target RNA is selected from PTBP1 RNA, AQp1 RNA or ANGPTL3 RNA.

28. The guiding polynucleotide according to claim 27, wherein The guide sequence is optionally selected from the sequences shown in SEQ ID NO: 5-6, SEQ ID NO: 42-49; preferably, the guide sequence is optionally selected from the sequences shown in SEQ ID NO: 5-6, SEQ ID NO: 43, SEQ ID NO: 45-47.

29. A CRISPR-Cas13 system, characterized in that It includes: The Cas13 protein according to any one of claims 1 to 8 or the fusion protein according to any one of claims 9 to 14, or a nucleic acid encoding the Cas13 protein or fusion protein; as well as a guide polynucleotide or a nucleic acid encoding the guide polynucleotide; the guide polynucleotide comprising a direct repeat sequence linked to a guide sequence engineered to hybridize to a target RNA; The guide polynucleotide is capable of forming a CRISPR complex with the Cas13 protein or fusion protein and guiding the sequence-specific binding of the CRISPR complex to the target RNA.

30. The CRISPR-Cas13 system according to claim 29, wherein The target RNA is selected from TTR RNA, SOD1 RNA, PCSK9 RNA, VEGFA RNA, VEGFR1 RNA, PTBP1 RNA, AQp1 RNA or ANGPTL3 RNA; alternatively, the target RNA is selected from PTBP1 RNA, AQp1 RNA or ANGPTL3 RNA.

31. The CRISPR-Cas13 system according to claim 30, wherein The guide sequence is optionally selected from the sequences shown in SEQ ID NO: 5-6, SEQ ID NO: 42-49; preferably, the guide sequence is optionally selected from the sequences shown in SEQ ID NO: 5-6, SEQ ID NO: 43, SEQ ID NO: 45-47.

32. The CRISPR-Cas13 system according to any one of claims 29 to 31, wherein The direct repeat sequence has at least 70% sequence identity compared to SEQ ID NO: 3 and any one of SEQ ID NOs: 80-87.

33. A CRISPR-Cas13 system, characterized in that It comprises the guiding polynucleotide or the nucleic acid encoding the same according to any one of claims 15 to 28, and the Cas13 protein or the nucleic acid encoding the same.

34. A vector system comprising the CRISPR-Cas13 system according to any one of claims 29 to 33, wherein The vector system comprises one or more vectors comprising a polynucleotide sequence encoding the Cas13 protein or fusion protein and a polynucleotide sequence encoding the guide polynucleotide.

35. An adeno-associated virus vector comprising the CRISPR-Cas13 system according to any one of claims 29 to 33, wherein The adeno-associated virus vector comprises DNA encoding the Cas13 protein or fusion protein and a guide polynucleotide.

36. A lipid nanoparticle comprising the CRISPR-Cas13 system according to any one of claims 29 to 33, wherein The lipid nanoparticle comprises the guide polynucleotide and the mRNA encoding the Cas13 protein or fusion protein.

37. A lentiviral vector comprising the CRISPR-Cas13 system according to any one of claims 29 to 33, wherein The lentiviral vector comprises the guide polynucleotide and the mRNA encoding the Cas13 protein or fusion protein; preferably, the lentiviral vector is pseudotyped with an envelope protein; optionally, the mRNA encoding the Cas13 protein or fusion protein is connected to an aptamer sequence.

38. A ribonucleoprotein complex comprising the CRISPR-Cas13 system according to any one of claims 29 to 33, wherein The ribonucleoprotein complex is formed by the guide polynucleotide and the Cas13 protein or fusion protein.

39. A virus-like particle comprising the CRISPR-Cas13 system according to any one of claims 29 to 33, wherein The virus-like particle comprises a ribonucleoprotein complex formed by the guide polynucleotide and the Cas13 protein or fusion protein; optionally, the Cas13 protein or fusion protein is fused with the gag protein.

40. A eukaryotic cell comprising the Cas13 protein of any one of claims 1 to 8, the fusion protein of any one of claims 9 to 14, the guide polynucleotide of any one of claims 15 to 28, or the CRISPR-Cas13 system of any one of claims 29 to 33; optionally, the eukaryotic cell is a mammalian cell.

41. A pharmaceutical composition, characterized in that It comprises the Cas13 protein according to any one of claims 1 to 8, the fusion protein according to any one of claims 9 to 14, the guiding polynucleotide according to any one of claims 15 to 28, or the CRISPR-Cas13 system according to any one of claims 29 to 33.

42. An in vitro composition, characterized in that It comprises the CRISPR-Cas13 system according to any one of claims 29 to 32, and a labeled detector RNA that cannot hybridize with the guide polynucleotide.

43. An isolated nucleic acid, characterized in that It encodes the Cas13 protein according to any one of claims 1 to 8 or the fusion protein according to any one of claims 9 to 14.

44. An isolated nucleic acid, characterized in that It encodes the guiding polynucleotide according to any one of claims 15 to 28.

45. Use of the Cas13 protein according to any one of claims 1 to 8, the fusion protein according to any one of claims 9 to 14, the guide polynucleotide according to any one of claims 15 to 28, the CRISPR-Cas13 system according to any one of claims 29 to 33, or the isolated nucleic acid according to claim 42 or claim 43 in detecting a target RNA in a nucleic acid sample suspected of containing the target RNA or in preparing a reagent for detecting a target RNA in a nucleic acid sample suspected of containing the target RNA.

46. ​​A use of a Cas13 protein according to any one of claims 1 to 8, a fusion protein according to any one of claims 9 to 14, a guide polynucleotide according to any one of claims 15 to 28, a CRISPR-Cas13 system according to any one of claims 29 to 33, or an isolated nucleic acid according to claim 42 or claim 43 for any of the following or for preparing a reagent for achieving any of the following schemes: cutting one or more target RNA molecules or nicking one or more target RNA molecules, activating or upregulating one or more target RNA molecules, activating or inhibiting the translation of one or more target RNA molecules, inactivating one or more target RNA molecules, visualizing, labeling or detecting one or more target RNA molecules, binding one or more target RNA molecules, transporting one or more target RNA molecules, and masking one or more target RNA molecules.

47. A method for diagnosing, treating or preventing a disease or condition associated with a target RNA, characterized in that: The Cas13 protein of any one of claims 1 to 8, the fusion protein of any one of claims 9 to 14, the guide polynucleotide of any one of claims 15 to 28, the CRISPR-Cas13 system of any one of claims 29 to 33, or the isolated nucleic acid of claim 42 or claim 43 is administered to a sample of a subject in need or to a subject in need.

48. Use of a Cas13 protein according to any one of claims 1 to 8, a fusion protein according to any one of claims 9 to 14, a guide polynucleotide according to any one of claims 15 to 28, a CRISPR-Cas13 system according to any one of claims 29 to 33, or an isolated nucleic acid according to claim 42 or claim 43 in the preparation of a medicament for diagnosing, treating or preventing a disease or condition associated with a target RNA.